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List of abbreviations 
 
α-syn: α-synuclein 
α-syn RT-QuIC: α-synuclein Real-Time Quacking-Induced Conversion  
AD: Alzheimer’s Disease 
AgD: argyrophilic grain disease  
AP: atypical parkinsonism  
ALS: amyotrophic lateral sclerosis  
AON: anterior olfactory nucleus 
ASA: Amyloid Seeding Assay  
BSE: bovine spongiform encephalopathy  
CAA: cerebral amyloid angiopathy  
cAMP: cyclic adenosine monophosphate  
CBD: corticobasal degeneration  
CJD: Creutzfeldt-Jakob disease 
CNS: central nervous system 
CSF: cerbrospinal fluid 
CTE: chronic traumatic encephalopathy  
FTD: frontotemporal dementia 
GBCs: globose basal cells 
HBCs: horizontal basal cells 
HD: Huntington’s disease  
IgA: immunoglobulin A  
IQ-CSF: Improved RT-QuIC assay for CSF 
IPTG: isopropyl b-D-1-thiogalactopyranoside  
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Olfactory impairment is considered an initial disturbance of several 
neurodegenerative diseases (NDs), including Parkinson’s disease (PD) and 
Alzheimer’s disease (AD). In addition, smell impairment precedes a decade, or 
even longer, the onset of motor or cognitive symptoms.  
Olfactory signals are detected by olfactory receptor proteins (ORPs) expressed in 
the cilia of olfactory receptor neurons (ONs). ONs are the distinctive cellular 
components of the peripheral olfactory epithelium (OE) and lie in the nasal vault.  
ONs axons pass the cribriform plate and reach the olfactory bulb (OB) where the 
olfactory stimuli are processed and sent to the superior nuclei of the CNS.  
Previous studies in AD and other neurodegenerative disorders have shown the 
presence of β-amyloid deposits in the OB, neurofibrillary tangles, as well as Lewy 
body pathology. OB represents the brain area earlier involved in the 
neuropathological process, decades before the development of clinical symptoms. 
Therefore, OB can be considered a target in the study of neurodegenerative 
diseases in their early molecular processes. Moreover, the OB of healthy subjects 
presents deposits of aggregated proteins confirming that these aggregates are 
deposited in a prodromal disease stage. 
Since the OB is an early accumulation site of aggregated proteins and the 
synapses derive from the ONs, it is possible that the first event of protein 
aggregation occurs in OE. ONs are directly exposed to the external environment 
including chemical/physical toxic injuries and such micro-environment 
predisposes to abnormal protein processing and folding (Sammeta and 
McClintock 2010).  
In addition, ONs and all other mature cell components have a half-life of three 
months and programmed apoptosis. The neural activity is maintained by a 
constant cellular turn-over, which is sustained by the basal stem cells. This 
regeneration process is persistent during the whole life of an individual, albeit 
with a decreasing rate with aging.  
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Extensive scientific literature indicates the neuronal damage as the consequence 
of exposure to toxic injuries leading to neurodegeneration and ONs are a natural 
model of this noxious process (Lema Tomé, Tyson et al. 2013). 
The hypothesis of this pathological pathway is supported by several studies, in 
which aggregated forms of α-synuclein, tau and β-amyloid are detected in 
olfactory mucosa (OM) biopsies as well as in autoptic samples of patients with 
Parkinson’s disease (PD), Lewy body dementia (LBD), Frontotemporal dementia 
(FTD) and Alzheimer disease (AD) (Funabe, Takao et al. 2013) (Saito, Shioya et 
al. 2016) (Tabaton, Cammarata et al. 1991) (Talamo, Rudel et al. 1989) (Crino, 
Greenberg et al. 1995) (Arnold, Lee et al. 2010). 
In this study, we investigated for the first-time primary ONs sampled ex vivo 
using olfactory brushing (OBg) in normal subjects and patients with different 
neurodegenerative disorders. Because of its convenient location, OE is easily 
accessible and can be sampled to obtain the ONs in the tissue outer layer. This 
sampling method is harmless and non-invasive, bypassing potential artifacts due 
to postmortem specimens as well as avoiding the invasiveness of biopsy 
procedures.  
Recently, we showed that OBg procedure in Creutzfeldt-Jakob Disease (CJD) 
patients allows efficient OM sampling for the Real-Time Quaking-Induced 
Conversion (RT-QuIC) assay. We specifically amplified pathological prion 
protein (PrP
Sc
) providing a diagnostic intra vitam test with sensitivity and 
specificity nearly to 100% (Orrú, Bongianni et al. 2014). 
For the purpose of our study, we firstly defined the phenotypic characterization of 
the human olfactory cells sampled with OBg from healthy subjects.  
Distinct antibodies were selected to analyze the olfactory epithelium cells: 
olfactory marker protein (OMP), neuron-specific class III β-tubulin (TUJ-1), 
protein gene product 9.5 (PGP 9.5), Pan-Cytokeratin (PCK).  
Secondly, we aimed to determine the expression patterns of the major misfolded 
proteins involved in the main neurodegenerative diseases. In particular, the 
selected proteins were: α-synuclein, APP/beta-amyloid, tau, and TDP-43. 
The identification of the expression patterns of these proteins in the ONs might 
provide information to understand the abnormal molecular mechanisms in the 
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initial misfolding species involved in the pathological process. Moreover, in this 
study, we speculated on the subcellular locale where the protein aggregation may 
occur. 
Furthermore, by demonstrating the constitutive expression of the native NDs-
associated proteins in the OE, we could assume that they may represent a potential 
template for triggering the aggregation process. 
Based on the immunocytochemistry analysis, we investigated the α-synuclein 
expression in patients affected by different synucleinopathies. In fact, α-synuclein 
misfolding and aggregation mechanisms are involved in the pathogenesis of 
neurodegenerative disorders such as Parkinson's disease (PD), dementia with 
Lewy bodies (LBD) and multiple system atrophy (MSA), which are all 
characterized by α-synuclein fibrils deposition (Spillantini, Schmidt et al. 1997). 
Finally, we analyzed the immunocytochemistry results in OM samples tested by 







1.1 Neurodegeneration and protein aggregation 
 
Neurodegeneration refers to the process of progressive atrophy (degeneration) 
and/or death of nerve cells, which characterizes neurodegenerative diseases 
(NDs). “Neurodegenerative diseases” is an umbrella term for a range of neuro-
pathological, incurable and debilitating conditions, which result in disturbances in 
movement (ataxias) and/or mental functioning (dementias). 
NDs principally affect neurons in the human brain. Neurons are the building 
blocks of the nervous system which includes the brain and spinal cord. In NDs, 
the progressive loss of selectively vulnerable populations of neurons diverges 
from the confined stationary neuronal loss caused by metabolic or toxic disorders. 
Neurons do not replicate and when they become disrupted or die, the organism 
cannot replace them, and their role and functions are lost. 
Neurodegenerative diseases can be classified according to primary clinical 
features (e.g., dementia, parkinsonism, or motor neuron disease), anatomic 
distribution of neurodegeneration (e.g., frontotemporal degenerations, 
extrapyramidal disorders, or spinocerebellar degenerations), and principal 
molecular abnormality. Dementias are responsible for the greatest burden of 
neurodegenerative diseases, with Alzheimer’s disease (AD) representing 
approximately 60-70% of dementia cases. 
NDs are extremely debilitating illnesses,  including: Alzheimer’s disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s 
disease (HD), spinocerebellar ataxias (SCA), frontotemporal dementia (FTD), 
corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), chronic 
traumatic encephalopathy (CTE), multiple system atrophy (MSA), dementia with  
Lewy bodies (LBD),  and prion diseases  (PrPD). Despite the widely different 
clinical symptoms and the vast variations in incidence that characterize NDs, they 
have many shared features, such as the chronic and progressive nature, increase of 
age-dependent prevalence, neural damage, synaptic network disruption and 
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degeneration of specific brain areas causing brain mass loss (Ross and Poirier 
2004). 
A wealth of research in recent years has revealed that many of the most common 
age-associated neurodegenerative diseases result from the transformation and 
accumulation of specific proteins within the nervous system. 
Protein misfolding, aggregation and accumulation are currently considered crucial 
events in NDs. These events in NDs provoke cellular dysfunction, synapses defeat 
and ultimately brain damage. Even though the proteins involved in each ND are 
different from each other, the central phenomenon of protein misfolding 
conducive to their aggregation is analogous.  
The process of misfolded protein aggregation is commonly defined as amyloid, 
and the consequent accumulation of such aggregated forms provides further 
crucial parallelism between the NDs. Moreover, it is thought to be the key event 
of their onset. Furthermore, the process of protein misfolding, the intermediates 
generated, the end-products, and other molecular and pathological features are 
extraordinarily comparable, although the protein aggregates produced are 
distinctive for each ND (Soto 2003). 
The finding that misfolded protein aggregates self-propagate by seeding activity 
represented an important advance in the understanding of the mechanisms leading 
to neurodegeneration. In this way, the aberrant forms of the specific proteins 
spread in the organism, from one cell to another, between tissues, imitating the 
infectious prion diffusion model. The consequences of such discovery were 
crucial to the comprehension of the initial mechanisms of NDs and the 
understanding of the ways in which they evolve. This novel perspective has also 
proved fundamental in developing experimental strategies for treatment and 
diagnosis (Soto and Pritzkow 2018). 
Hundreds of significant shreds of evidence from in vivo and in vitro studies, both 
in human and mouse models, supported the theory that the protein misfolding, 
oligomerization and accumulation are the key mechanisms that initiate the 
pathology and its progression (Goedert 2015). 
The most frequent aggregated proteins in NDs are:  the amyloid precursor protein 
(APP) peptide amyloid-beta (Aβ) in AD; tau in AD, FTD,  CBD, PSP, 
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argyrophilic grain disease (AgD), CTE; α-synuclein (α-syn) in PD, LBD and 
MSA; TAR DNA-binding protein 43 (TDP-43) in ALS and FTD; and prion 
protein (PrP
Sc
) in PrPDs (i.e., Creutzfeldt–Jakob disease (CJD), bovine 
spongiform encephalopathy (BSE), Variant Creutzfeldt–Jakob disease (vCJD). 
Surprisingly, these neurodegeneration-associated proteins do not share common 
features in terms of primary, secondary or tertiary structure, either in size, 
expression level, cellular localization, or function. Conversely, all these proteins 
easily undergo misfolding from their native structure resulting in β-sheet-rich 
multimers and oligomers in the ill brain. This process goes further without 
interruptions, until it forms bulky fibrils and tangles (Ross and Poirier 2004).  
The amyloids aggregates arrangement is particularly defined, with a size between 
100 and 200 Å in diameter, and consists of a cross-β framework, a structure of 
intermolecular β-sheets array running parallel to the long axis of the fibrils 
(Fitzpatrick, Debelouchina et al. 2013). Typically, specific dyes, such as Congo 
red, thioflavin, and their derivatives are used to identify these amyloid species 
through staining techniques (Rambaran and Serpell 2008). 
At first, aggregates of these NDs-associated proteins, deposited in the brain, were 
considered the neurotoxic agents. However, recent evidences coming from 
successive investigations suggested a new experimental clue: the triggering 
species should be the soluble misfolded oligomers, acting as precursors of the 
fibrillar structures, which in turn would be the actual causes of ensuing 
neurodegeneration (Caughey and Lansbury Jr 2003). 
The species included in the vague and heterogeneous definition of misfolded 
oligomers extends from dimers to superior protofibrillar structures, to which 
hundreds of monomers can merge (Rambaran and Serpell 2008). 
The process of protein misfolding and aggregation consists of rearranging the 
secondary and the tertiary structures of the protein and to end, obviously, the 
quaternary structure. The molecular mechanism resides in the conformational 
change of the regular protein into numerous sequences of β–strands. 
Subsequently, hydrogen bonds and hydrophilic interactions then stabilize the 
conformations acquired. Exposed ‘sticky’ ends from these strands trigger the 
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incorporation of other regular or not yet completely aberrant proteins into the 
cross-β polymer.  
This misfolding process is highly protean and is in equilibrium between 
monomers and fibrils. Some of these species are on-pathway intermediates for 
amyloid fibril elongation, whereas some others could be terminal off-pathway 
products, causing possible toxic effects. Hence, the identification of the principal 
oligomeric species in the seeding activity and the achievement of high-resolution 
information about their structure is very challenging and particularly hard because 
of their quick interconversion, the vast heterogeneity and their tendency to 
generate stable higher-order aggregates (Breydo and Uversky 2015). 
Jarrett and Lansbury in 1993 proposed for the first time the kinetic model of the 
protein misfolding and the related aggregation mechanism (Jarrett and Lansbury 
Jr 1993). According to the theory, the entire process is divided into two principal 
phases: the initial nucleation, slow and thermodynamically unfavorable, and the 
fast and facilitated elongation stage. It appears clear that the bottleneck in this 
process is the formation of a stable seed, which in turn should act as a nucleus for 
further polymerization that irreversibly and rapidly continues to gobble monomers 
to feed its growth. Therefore, the bottleneck in this model is the first crucial phase 
in the formation of the nucleus (Soto, Estrada et al. 2006).    
Still unknown are the causes that promote the phenomenon in vivo by which the 
bulky polymers generated start to fractionate in new seeds with ensuing 
propagation and spread of the aggregation reaction. There are further open issues 
that need to be clarified in the model regarding the regular protein recruitment into 
the mounting aggregates, in which the elongation rate notably increases, as well as 
the propagation grade, and that may also indirectly provoke toxic effects for 
essential protein removal.  
Furthermore, diverse conformational strains may derive from the single 
molecules, which can assume several organization systems, even though the 
primary scaffold of the aggregates appears analogous. However, it should be 
remembered that, despite their similarities, every single ND differs from the 




The main differences within NDs, apart from the crucial hallmark that in each 
disease are distinctive proteins which preponderantly aggregate, involve the 
following traits: clinical signs, prevalence, brain area and cell types of affection, 
genes implicated and risk factors. Also, the cellular location of expression and the 
aggregation locale change from a disease-associated protein to another. 
As a final point, it has been demonstrated that the inner structure and the 
molecular arrangement of each specific aggregate have distinctive features 
depending on the protein involved and the affecting disease (Soto and Pritzkow 
2018). 
The hypothesis formulated to explain this last concept claims that all these 
particular differences in primary sequence, gene regulation, and expression pattern 
may influence the misfolding mechanism and the ensuing dynamic of 
aggregation, thence the cellular toxicity pathway, and in the end, the evolution of 




1.2 Prion paradigm and spread of proteinopathies 
 
The contemporary emerging theory about NDs-associated proteins suggests that 
they mimic a prion-like mechanism of seeding and spreading. 
 
 
Fig. 1 Schematic draw representing the main steps leading to the spread of 
proteopathic seeding activity. Normal proteins (green) stochastically undergo to 
misfolding, thereby generating disease-specific seeds (orange). When the formation of the 
seed occurs, the starting disrupted proteins become inactive and start to self-assemble into 
multimers. Once the seeds are released, they may move from one location to another by 
several potential pathways. The local vulnerability for the seeds transfer and replication is 
selective, depending on the cell type and the recruitment of auxiliary agents. The 
compatibility of the transport and uptake mechanisms affect the pathological spread (the 
further propagation of the seeds is halted in the dark blue cell). Also, differences among 
cells in the expression level, isoform maturation and cellular localization of the starting 
proteins may modulate the nature and the behavior of seeds, so that the distinct strains 
produced follow distinct propagation pathways. 
 
Growing pieces of evidence from recent important studies support this concept of 
pathology propagation of all NDs-associated proteins. (Walker and Jucker 2015). 
Proteins that share this propagation prion-like principle consists of α-synuclein, 
amyloid-β, tau and TDP-43. Alpha-synuclein forms Lewy bodies and Lewy 
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neurites in PD and Lewy body dementia, as well as glial cytoplasmic inclusions in 
multiple system atrophy. Amyloid-β results in amyloid plaques and cerebral 
amyloid angiopathy (CAA) in AD. Tau protein causing neuronal and/or glial 
tauopathies in AD, chronic traumatic encephalopathy, and other NDs. TAR DNA-
binding protein-43 (TDP-43), instead, is the principal protein associated with ALS 
and frontotemporal dementia (Goedert 2015). 
Taken for granted the aberrant misfolding activity of these proteins in the 
constitution of the related diseases, the pathologic seeds following this principle 
can be transmitted between cells and tissues. 
In support of this hypothesis, cross-sectional examinations have constantly shown 
that the presence and the distribution of the histopathological lesions do not occur 
and diffuse casually. Somehow, their incidence follows a precise and outlined 
pattern in space and temporal course (Braak and Braak 1991)(Brettschneider, Del 
Tredici et al. 2015). 
Data coming from in vivo imaging analyses in the last years reaffirm the 
postmortem histopathological findings according to which the neural connectome 
is the means by which pathological lesions diffuse from one region to another 
(Iturria-Medina and Evans 2015). 
Of course, for the pathology spreading to another district, receptive areas need to 
be compatible and to some extent favorable for the retention and propagation of 
the pathogenic agents.  
Unfortunately, the mapping of the pathology diffusion in the human brain through 
the postmortem examinations and in vivo imaging recounts the dynamic 
development of the disease in a surrogate way. Indeed, the tools of investigations 
routinely used to look at the brain lesions to reveal the sites of distribution, 
missing the information on the activity of the aberrant pathological seeds and the 
related sequelae (Collinge 2016). 
The definition of prion-like recalls the amyloid-prone nature of the NDs-
associated proteins. In this regard, it is important to take into consideration that 
small oligomeric species are also produced by the same proteins. As a 
consequence, it is reasonable to hypothesize that the molecular species produced 
may also affect the cells and disrupt their function and homeostasis. 
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Unfortunately, at the state of the art, there are no assays specific and sensitive 
enough for the detection of such molecular species in vivo. Therefore, we can 
conclude that even though the presence of proteopathic deposits is a clear claim of 
the disease, this evidence is not always necessary for the instauration and the 
progression of the pathology (Jucker and Walker 2018). 
All the misfolded protein aggregates own this propensity to the seeding activity, 
and along with this feature, like the transmissible prion, they acquire the spreading 
intrinsic capacity of the aggregation process (Soto, Estrada et al. 2006).  
In the prion infectivity, after the long polymers have formed, they spontaneously 
start their fragmentation, triggering the release of new seeds. This mechanism 
increases the rate of prion propagation, and following the seeding–nucleation 
model, PrP
Sc
 latently spreads in the brain until it reaches the toxic threshold 
resulting in cellular dysfunction, damage, and lastly clinical disease. (Soto 2012). 
Given the fact that, as mentioned above, all NDs-associate proteins own the 
seeding aggregation activity, it has been hypothesized that potentially they may 
also have infectious abilities similar to those of the prions. This point is still 
strongly debated, even though it is supported by several studies demonstrating the 
pathological transmission of protein deposits in amyloidosis mice models (Xing, 
Nakamura et al. 2001). 
An increasing number of investigations in cellular and animal models have 
brought data in favor of this concept providing evidence that NDs in experimental 
conditions can be transmitted via a prion-like mechanism.  
The first NDs-associate protein, whose transmissibility has been demonstrated , 
according to a prion-like modality, was Aβ (Ganowiak, Hultman et al. 1994). A 
pioneering study in a transgenic mouse model showed that seeds of amyloid-β in 
brain extracts are necessary and sufficient to trigger protein aggregation (Jucker 
and Walker 2013). 
Notably, these studies have shown that Aβ, tau, and α -synuclein are able to 
induce the pathology in cell cultures or animal models inoculated with tissue 
homogenates of NDs patients or transgenic mice (Goedert 2015) (Soto 2012) 
(Jucker and Walker 2018). Similar studies showed analogous results with purified, 
synthetic and/or recombinant proteins components (Jucker and Walker 2018). 
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Taking into account that tissue homogenates are more transmission-prone, also 
other cellular aspects probably influence the pathological induction too (Walker 
and Jucker 2015). 
Still discussed is the question of whether the spreading of protein misfolding 
corresponds to the spreading of disease. In some circumstances, the induction of 
the pathology is limited to the accumulation of protein aggregates, while in others 
it matches with tissue lesions and clinical signs, which are typical of each disease 
(Soto and Pritzkow 2018).  
Finally, it must be considered that the transmission of the biological information 
through the seeding of protein aggregation, is organized at multiple levels 
(Goedert, Falcon et al. 2014). 
At the first molecular level, the conversion of normal proteins elicits the 
autocatalytic growth of aggregates. When the process is observed at the cellular 
level, the spreading of the pathology from cell to cell can be noticed, transferring 
the aggregates between contiguous cells, which in turn spread locally the aberrant 
deposits. Secondly, at the organ level, this transfer among cells provokes tissue 
damage, that can be transmitted to distant brain areas. Lastly, at the level of the 
organism, the transmission of the seeds can induce systematically the protein 
misfolding process like an infectious disease. Nevertheless, in the NDs, only the 





1.3 Synucleinopathies  
 
The term synucleinopathies derives from the name of the protein α-synuclein, 
which is the main pathologic agent involved in this subset of NDs. Three major 
disturbs can be identified in this class of NDs: PD, LBD, and MSA, but also rarer 
neuro-axonal dystrophies are encompassed in (Goedert, Jakes et al. 2017). 
The principal pathological hallmark shared by all disorders included in this 
disease classification is the presence of pathological aggregates of insoluble, 
fibrillar α-synuclein in selective populations of neurons, nerve fibers and\or glial 
cells (Goedert, Jakes et al. 2017). 
PD is the second most common NDs after AD and affects approximately seven 
million people globally and one million people in the USA. It has an estimated 
prevalence of 0,3 % in the general population and 1% in people aged over 60 (De 
Lau and Breteler 2006). The most evident and typical symptoms of PD are motor 
dysfunctions such as: bradykinesia, resting tremor, posture instability, and 
rigidity. These events are due to low levels of dopamine caused by the selective 
death of dopaminergic neurons in the substantia nigra pars compacta (SNc) 
(Jankovic 2008). 
The progression of the pathology denotes the onset of non-motor symptoms like 
cognitive impairment, sleep disorders, depression, and sensory symptoms 
(Chaudhuri, Healy et al. 2006). The principal pathological hallmark of PD is the 
formation of eosinophilic, intracellular fibrillary inclusions of aggregated α-
synuclein and other proteins in the brain stem called Lewy bodies and Lewy 
neurites (Spillantini, Schmidt et al. 1997). 
PD occurs in two principal manifestations: sporadic or familial, and in this 
inherited form, the genetic autosomal transmission is the causing factor derived 
from mutations in one of these genes, either in a dominant or recessive way: 
SNCA, LRRK2, PRKN, PINK1 and DJ-1 (Polymeropoulos, Lavedan et al. 1997) 
(Selvaraj and Piramanayagam 2019). 
Unfortunately, at present, there is no cure for PD; however drugs like L-DOPA, 
dopamine agonists, and MAO-B inhibitors, as well as surgical treatments like 
deep brain stimulation, can be used to alleviate symptoms (Connolly and Lang 
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2014). Studies in animal model have demonstrated that the immunization, either 
active or passive, is able to reduce the α-synuclein levels. Following these 
encouraging results, the possibility to start α-synuclein vaccination programs is 
under examination, and some of them are being evaluated in clinical trials 
(Masliah 2005) (Sanchez-Guajardo, Annibali et al. 2013). 
After AD, LBD is the second most common form of dementia. It affects 
approximately 15% of all dementia patients (McKeith 2007).  
Excluding the core hallmark of dementia, the other crucial symptoms of LBD are 
fluctuating cognition, parkinsonism, REM sleep behavior disorder (RBD), and 
sensory hallucinations, particularly visual. For these reasons, patients suffering 
from RBD are considered affected by one early stage of a synucleinopathy, which 
will overt definitively in the future. 
The early pathology markers of LBD are Lewy bodies in the cortical areas that 
subsequently, with the progression of the disease, extend largely in the brain.  
Notably, PD and LBD have a lot of common features and show an overlapping 
neuropathological profile in some points that render the defined and net diagnosis 
very difficult (McKeith, Boeve et al. 2017). 
MSA is a rarer disease than the above described NDs. The prevalent symptoms 
associated with MSA are: autonomic failure, cerebellar ataxia, parkinsonism, 
urinary dysfunction and corticospinal disorders (Gilman, Wenning et al. 2008).  
Currently, the estimated annual incidence rate is 3 new cases per 100.000 people 
(Bower, Maraganore et al. 1997). The pathology map primarily covers the 
striatonigral and the olivopontocerebellar areas of the brain, with characteristic α-
synuclein cytoplasmatic inclusions in glial cells (Gilman, Wenning et al. 2008). 
However, the fibrillary inclusions of α-synuclein are histopathological markers 
found also in significant number of patients with different NDs. For instance, a 
fluctuating grade between 7-30% of AD patients is positive for Lewy body 
inclusions together with the extracellular β-amyloid plaques and tau tangles 
(Hamilton 2000). 
Other forms of synucleinopathies are pure autonomic failure (PAF) and neuro-






Alpha- synuclein is a protein consisting of 140 amino acids primarily expressed in 
the CNS, especially in the presynaptic nerve terminals (Jakes, Spillantini et al. 
1994). 
Together with β-synuclein and ɣ-synuclein, α-synuclein composes the synuclein 
protein family which has only been described in vertebrates (George 2001). 
Originally, it was discovered in human when Uéda and colleagues purified a short 
peptide from the amyloid β-plaques of AD patients, named it the non-amyloid 
component (NAC). In this pioneering study the precursor protein of the isolated 
peptide was also described for the first time, referring to it as the non-amyloid 
component precursor protein (NACP) (Uéda, Fukushima et al. 1993). 
Previous studies should have found the same protein in Torpedo electroplaques 
and rat brain, then described as a “neuron-specific presynaptic nerve terminal 
protein localized to the nucleus and presynaptic nerve terminal” and for this called 
“Synuclein” (Maroteaux, Campanelli et al. 1988).  
From a structural point of view, it is possible to divide the α-synuclein protein into 
three domains. Firstly, the amino-terminus (N-terminus) domain, which interacts 
with lipids (1-60). Secondly, a central core region, which includes the NAC 
peptide and that is hydrophobic (61-95). Lastly an acidic carboxyl-terminus (C-
terminus) characterized by random coil structure (96-140). 
Inside the first two domains, there are imperfect repeats, comprising 11 amino 
acids each and with a KTKGEV consensus sequence (George 2001). 
Within the synuclein family, the only highly conserved sequence is the N-













Fig. 2 A. Nuclear magnetic resonance (NMR) prediction of micelle-bound human 
alpha-synuclein structure. The N-terminal region (in blue, 1-60) is amphipathic and 
binds lipids. In the center, there is the hydrophobic region (yellow/orange, 61-95) also 
called NAC. The C-terminal region (red, 96-140) presents a random coil arrangement. In 
the N-terminal region there are all the missense mutations associated with familial PD 
(A30P, E46K, H50Q, G51D, A53T, and A53E).1xq8, from the protein data bank: (Ulmer, 
Bax et al. 2005). B. Atomic-resolution structure by solid-state NMR spectroscopy of a 
pathogenic fibril of full-length human α-synuclein in a form that induces robust pathology 
in primary neuronal culture. 2N0A, from the protein data bank (Tuttle, Comellas et al. 
2016). 







Normally, α-synuclein in the cytosol of cells in physiological conditions has no 
defined folding, showing just a hint of slight secondary structure (Fauvet, Mbefo 
et al. 2012).  
Nevertheless, it has been advanced that, although α-synuclein is naturally 
unfolded, in its native state it spontaneously assumes a stable quaternary structure 
over time. This structure consists of homo-tetramers with a helically folding and it 
has been proposed that this molecular species does not aggregate (Bartels, Choi et 
al. 2011). 
There are also two hypothetical foldings with α-heliacal conformations, a single 
extended α-helix or two anti-parallel α-helices, which come to be formed in the N-
terminus domain when the protein binds the lipids (Ferreon, Gambin et al. 2009). 
Alpha-synuclein preferentially binds the membrane in those points where it is 
curved because its N-terminal domain promotes that shape (Westphal and 
Chandra 2013). In several structural studies it has also been observed that α-
synuclein forms multimers when it is in contact with cellular membranes (Burré, 
Sharma et al. 2014). 
The proteopathic features of α-synuclein have emerged when it has been isolated 
as the main fibrillar component of the Lewy bodies and Lewy neurites 
(Spillantini, Schmidt et al. 1997). 
The pathological implications of α-synuclein have been reinforced thanks to the 
discovery of duplications and triplications (Singleton, Farrer et al. 2003) and six 
missense point mutations (A53T, A30P, E46K, H50Q, G51D, and A53E) in 
familial forms of NDs, hence called synucleinopathies. Moreover, variants of 
SNCA have been associated with sporadic forms of PD in genome-wide 




1.4 Braak staging and dual hit hypothesis in synucleinopathies 
 
In PD and other parkinsonism, the occurrence of motor symptoms becomes 
evident only after the death of the 60% of neurons in the substantia nigra pars 
compacta (SNc), harboring the ventral midbrain A9 dopaminergic population, 
leading to 80% dopamine depletion in the putamen and caudate nucleus of the 
striatum (Cheng, Ulane et al. 2010). 
Since medical practice provides the diagnosis principally from clinical signs, the 
pathology is evaluated and may be counteracted at the advanced stages. When the 
disease arrives at the end-stage the dopaminergic neurons are just dying or dead, 
rich inner the cytoplasm of aggregates with abundant Lewy bodies inclusions. 
The motor functions decline over a period of 10 years after the diagnosis in the 
majority of the patients, when other non-motor manifestations like sleep disorders, 
dementia and depression may occur (Chaudhuri, Healy et al. 2006). 
For that reason, it is reasonable to assume that also different neuronal populations 
could be involved in the onset and the progression of the pathology. This concept 
is also reinforced by the disease spreading pattern depicted by Braak staging in a  
pioneering work (Braak, Tredici et al. 2003). 
The hypothesis underlining this pathology diffusion representation stipulates that 
the aberrant α-synuclein aggregates spread throughout the CNS via the olfactory 
bulb and/or gastrointestinal tract, entering the medulla oblungata and pontine 
tegmentum at the first two stages of the disease. 
From these two peripherical brain districts, as the ongoing pathology spreading in 
the midbrain progresses, in stages 3-4, the lesions have invaded the substantia 
nigra. In the final 5-6 stages, the pathology brain contamination progress to the 
neocortex (Braak, Ghebremedhin et al. 2004). These indications suggest that the 
dopaminergic neurons are not the primary cellular carries of the pathology, but the 
more susceptible neuronal type to the related damage.  
Braak and co-authors advanced the ‘dual-hit hypothesis’ about the pathogenesis of 
idiopathic PD. According to this “dual hit” theory, an unknown etiopathological 
agent akin to a slow-virus may enter the nervous system through both the nasal 
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and intestinal mucosa, eventually resulting in a cascade of events that leads to the 
pathology in the brain (Hawkes, Del Tredici et al. 2007). 
This line of thought may explain the bowel irritability and the olfactory loss, 
which anticipate the disease up to decades (Braak, de Vos et al. 2006). 
Additionally, the successive development of dementia and/or depression in the 
following stages of the disease also reflects the Braak staiging mapping (Beach, 
Adler et al. 2009). 
Further indications of the olfactory bulb as a possible spreading site of the 
pathology in the CNS are obtained from neuropathological studies examining the 
brains of neurologically normal individuals who are found to have incidental 
Lewy bodies. This study shows that the olfactory bulb is the most frequently 
affected brain region when only one region is involved in those cases with 
incidental Lewy bodies (Beach, Adler et al. 2009). 
However, it must be pointed out that Braak’s hypothesis is frequently debated, 
and the disease, that is constitutively heterogeneous in forms and evolution, not 
always follows the pathway delineated by Braak et al. (Burke, Dauer et al. 2008). 
Still, on grounds of the theories claiming this thesis, it is important to remark that 
the spreading of the pathology and the staging progressive course of the disease in 
PD and parkinsonisms are widely accepted.
 
 
Fig. 3 Braak staging of Parkinson’s disease. In the first two stages, the pathology 
spreading is located in the pons and the olfactory bulb. The pathology successively 
invades the limbic systems. In the final stages, the spreading reaches the neocortex. 
Taken and modified after Braak et al. 2003.  
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1.4.1 Propagation of synucleinopathies 
 
In synucleinopathies, the aggregates of α-synuclein shows different behaviors 
depending on the specific disease. In PD and LBD, the typical pathological 
deposits consist of Lewy bodies and Lewy neurites while in MSA α-synuclein 
aggregates have the form of glial cytoplasmic inclusions (Goedert, Spillantini et 
al. 2013). 
Following the prion principle, α-synuclein pathology seeded in a specific brain 
area is propagated along anatomically associated structures (Luk, Kehm et al. 
2012) (Luk, Kehm et al. 2012). This mechanism of spreading seems to be driven 
by selective neuronal transport of the seeding agent (Rey, Steiner et al. 2016). 
Probably, both the active and passive mechanisms promote the propagation of the 
α-synuclein seeds. The active axonal transport along specific neural pathways 
permits the movement of several components such as macromolecules, organelles, 
and viruses towards and out of the cell body of neurons. Both the anterograde and 
retrograde transport along axons have been described in vitro for Aβ, huntingtin, 
and α–synuclein, albeit with different transport rates (Brahic, Bousset et al. 2016). 
One of the misfolded α-synuclein alternative secretion pathway reported is 
mediated by the ubiquitin-specific protease 19 (Lee, Takahama et al. 2016). What 
emerges from these studies is a selective propensity of each cell line and each 
brain area to the neurodegeneration governed by differential trafficking of the 
pathological agents. 
Even more complex is the understanding of the global process considering the 
alterations in the host organism and the modifications to the pathological seeds 
during the course of the disease.  
Moreover, the spreading of the pathology throughout the brain is stimulated by 
the neuronal activity (Bero, Yan et al. 2011)(Yamada and Iwatsubo 2018). Even 
though the pathology dissemination is mediated by the neuronal connectivity and 
its activity, the increasing lesions provoke damages to the connectome integrity, 
as the disease progresses. This event might impair both the relative physiological 
function and thus spreading pathways (Palmqvist, Schöll et al. 2017). 
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As a final point, microglia also play a key role in the transport and processing of 
pathological seeds. Despite that, the modality by which its activation and its state 
impact on the phenotype of the disease are not completely clear (Asai, Ikezu et al. 
2015). 
In conclusion, according to the prion principle, other NDs have a time-consuming, 
silent phase in which the aberrant aggregates propagate, although not already 
sufficiently to provoke the pathological hallmarks or to be identified by the state-





1.5 Neurodegeneration and olfaction 
 
The indications coming from epidemiology studies suggest the possibility to use 
the olfactory mucosa as a potential early marker of NDs and other neurological 
disorders (Godoy, Voegels et al. 2015) (Doty 2009). 
Important considerations have to be made about the proposal of olfactory testing 
as a convenient tool in the differential diagnosis of several NDs (Doty 2009). 
The olfactory dysfunctions are assessed in three distinct abilities: detection, 
recognition, and memory. The capacity to remember odorants is particularly 
important in elderly patients, especially in AD (Jürgen M. Peters, Thomas 
Hummel et al. 2003). 
Interestingly, the olfactory impairment in AD patients starts in a pre-clinical 
period of the disease, preceding the onset of the typical motor and cognitive 
symptoms (Doty 2009). 
In addition, olfactory problems are also frequent in AD subjects, such as those 
who suffer from mild cognitive impairment and those with subjective memory 
complaints (Jürgen M. Peters, Thomas Hummel et al. 2003) (Doty 2008). 
Given the correlation between the olfactory impairment and the disease 
progression, it is feasible to use olfactory testing as a differential diagnostic tool 
for major AD. Furthermore, it may have clinical value as an early pathological 
marker in the diagnosis of incident AD in subjects at risk (Jürgen M. Peters, 
Thomas Hummel et al. 2003).  
Moreover, the apolipoprotein E-4 allele is an increasing risk factor of almost five-
fold concerning developing cognitive decline in anosmic subjects without 
neurological deficits (Doty 2009). 
Interestingly, the majority of the AD and PD patients with olfactory dysfunction 
are unaware of their deficit before the smell test result; nevertheless, up to 90% of 
these patients already have smell loss at the early stages of the pathology 
correlating with reduced activation of the central odor processing brain areas, 
demonstrated also by functional imaging (Doty 2009). 
In PD, as already mentioned above, olfactory impairment is a well-characterized 
and very recurrent non-motor symptom with a prevalence that varies from 50% to 
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90%. The olfactory loss often emerges as hyposmia at the beginning of the disease 
(Boesveldt, Verbaan et al. 2008). 
This evidence is in agreement with the hypothesis by which the olfactory bulb is 
the initial site of α-synuclein pathology spreading, successively propagated to the 
cerebral cortex via the rostral brainstem (Braak, Tredici et al. 2003). 
In line with this concept, the presence of Lewy bodies in the olfactory bulb used 
as a pathological marker corresponds to a sensitivity of 95% and a specificity of 
91% in PD deceased individuals. Furthermore, the α-synuclein pathology density 
grading in the olfactory bulb correlates with the unified Parkinson's Disease rating 
scale (UPDRS) motor scores (Beach, White et al. 2009). 
Other olfactory system areas in which pathological modifications are present 
include the anterior olfactory nucleus (AON), cortical nucleus of the amygdala, 
piriform cortex, olfactory tubercle, entorhinal cortex, and orbitofrontal cortex.  
The involvement of the AON in the α-synuclein pathology is not surprising, 
indeed, as this brain region is strictly connected with the olfactory bulb and the 
presence of the Lewy pathology here is indicated also by neuronal damage 
(Pearce, Hawkes et al. 1995). 
The idea that the α-synuclein pathology spreading inside the olfactory system 
from the peripheral to the central structures is also a part of the “olfactory vector 
hypothesis” and shares some conceptual points with the general “dual hit” theory. 
Growing pieces of evidence support the idea that the PD pathology is prematurely 
located in the olfactory bulb and its connected structures, starting from the 
periphery (Doty 2008). 
Besides, tau pathology has been shown in the AON in PD cases. Notably, in these 
studies, no tau aggregates in the AON of patients have been found (such as those 
with CBD and PSP), showing absent or slight olfactory impairment. For this 
reason, it has been proposed that tau protein also contributes to elicit olfactory 




1.6 Anatomy and physiology of the peripheral olfactory system 
 
Olfaction is one of the primitive senses and consists of perceiving and 
distinguishing odors (Heymann 2006) (Krieger and Breer 1999).  
Everyone has a unique capacity of smell, which allows us to perceive and 
communicate with the environment around us (Wysocki and Preti 2004). 
A series of mental processes are in relation to smell. It is known that smell evokes 
memories and that the memory pathway is linked to the olfaction (Richardson and 
Zucco 1989). Emotions, such as fear and anxiety, are transmitted through smell 
and also mating behaviors are provoked by smell (Wyatt 2014). 
Anatomically, the nasal cavity, in which the olfactory mucosa allowing olfaction 
through olfactory receptors is contained, extends from the nares through the 
external nose and as far back as the posterior nasal apertures or choanae, where 
the nasal cavity connects with the nasopharynx (Agur, Grant et al. 2005). 
The nasal cavity is composed of floor, medial and lateral walls, and roof. It is 
separated sagittally into right and left halves by means of the nasal septum. Each 
half of the nasal cavity is approximately 5 cm high and 6 cm long. Its shape 
results narrow transversely given that it is 1.5 cm circa wide at the floor and the 
same at the roof, (Sinnatamby 2011). 
The nasal cavity starts anteriorly with the vestibule, and from there, most of the 
surface is occupied by the respiratory region, while the restricted and variable 
olfactory area is principally confined to its postero-superior parts as well as the 
upper regions of lateral and medial walls (Morrison and Costanzo 1990). 
The respiratory mucosa extends anteriorly from the limen nasi, where it is 
continuous with the skin of the nasal vestibule throughout the nose and into the 
semi-superior part of the nasopharynx. It also extends into the sinuses, through 
their ostia and prolongs in the epithelia of the nasolacrimal duct and Eustachian 
tube. In the upper side, it is in continuity with the olfactory mucosa (Jafek, 
Murrow et al. 2002). 
The main olfactory mucosa has a surface of approximately 10 cm
2
,  lining from 
the posterior upper parts of the lateral nasal walls, comprising the superior 
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concha, the sphenoethmoidal recess, the upper part of perpendicular plate of the 
ethmoid, to the roof of the nose arching between the septum and the lateral wall, 
until the basement of the cribriform plate of the ethmoid bone. 
Recent anatomical studies of the peripheral olfactory system have changed the 
former notion of the olfactory mucosa distribution area. Previously, the 
neuroepithelium was considered circumscribed to the area of the cribriform plate, 
superior turbinate, and the opposite superior nasal septum (Escada, Lima et al. 
2009). The last discoveries resulting from Leopold’s anatomical study extends the 
olfactory mucosa within the medial and anterior surface of the middle turbinate, 
either in the lateral or in the medial wall of the nasal cavity (Leopold, Hummel et 
al. 2000). This new notion does not conflict with Biedlingmaier and Whelan’s 
previous report on the middle turbinate, in which they did not find olfactory 
sensory tissue. In fact, their studies focused on a more inferior middle turbinate 
level, where the olfactory epithelium is not present (Biedlingmaier and Whelan 
1996) (Leopold, Hummel et al. 2000).  
Unlike the rodents, in which there is a clear delineation between the two epithelial 
types, sensory olfactory epithelium in humans is often intermingled with 
respiratory tissue along the superior turbinate and septum (Welge-Lüssen and 
Hummel 2004).The olfactory mucosa consists of a considerably thicker 
pseudostratified olfactory epithelium (up to 100 µm), which contains 
approximately 6 million of the distinctive olfactory neurons and an underlying 
connective lamina propria (Lane, Gomez et al. 2002, Jafari 2006). 
Four principal types of cells compose the olfactory epithelium: olfactory receptor 
neurons, sustentacular/supporting cells, basal cells (stem cells) and the microvillar 
cells (Morrison and Costanzo 1990).  
Olfactory neurons are bipolar neurons with a cell body which is generally located 
in the middle-upper stratum of the epithelium, intermingled with the sustentacular 
cells and with a density in the tissue of 30,000/mm
2
 (Escada, Lima et al. 2009) 
(Moran, Rowley et al. 1982). Their single thin axon spread out from its basal 
edge, overcomes the lamina propria and gathers together the adjacent axons in an 
unmyelinated nerve fiber encompassed of glial ensheathing cells. In the opposite 
direction, they present a dendrite that ascends up to the most exterior layer of the 
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epithelium in which the apical knob branches 10-20 slender olfactory cilia (Bloom 
and Engström 1952). Olfactory neurons have an elliptical, dark nucleus in the 
middle of their cell body. Along the membrane they present gap junctions to 
communicate with the neighbor cells, helping the signal transduction and allowing 
their common renewal and their maturation (Delay and Dionne 2003). Once the 
olfactory nerve fibers enter the lamina propria joining in fila olfactoria they pass 
through the cribriform plate to establish synapses with the mitral/tufted cells of 
the olfactory bulb, forming the olfactory glomeruli.  
The sustentacular cells are irregular columnar cells separating olfactory neurons 
and sustaining the tissue structure. They have a large, vertically elongated, 
euchromatic nucleus that resides in a superior level of the neurons perikaryal layer 
(Weiler and Farbman 1998). The apical ending of the sustentacular cells gets to 
the external surface of the epithelium bearings abundant and irregular microvilli. 
In particular, among that microvilli, the long trailing neurons’olfactory cilia 
elongate into the mucous layer (Polyzonis, Kafandaris et al. 1979). The cytoplasm 
of the sustentacular cells is characterized by many mitochondria, granular and 
mainly agranular endoplasmic reticulum. Proximate to the epithelial surface their 
plasma membrane has fine microfilaments structure attached to desmosomes in 
order to give mechanical support to the tissue. Tight junctions are present between 
sustentacular cells and olfactory neurons (Morrison and Costanzo 1990). 
The basal cells are small, round or cone-shaped cells that form a distinct layer in 
the epithelium, resting on the basal lamina. Since they are stem cells, they 
represent the source of cellular components replacement for the epithelium 
renewal. During their commitment, they can differentiate in olfactory neurons or 
sustentacular cells depending on the particular stimuli received. In this way, they 
ensure the normal turnover or the regeneration after injuries (Graziadei and 
Graziadei 1983). 
Basal cells are divided into two categories: quiescent horizontal basal cells 
(HBCs), and the proper globose basal cells (GBCs). While the HBCs are long-
lasting progenitors activated exclusively when massive injuries occur to the OE, 
GBCs are “upstream” stem and progenitor cells, with multipotent stem capacity 
(Leung, Coulombe et al. 2007) (Krolewski, Packard et al. 2013). However, they 
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are well-described in rodent and it is known that the sustentacular cell end with 
“feet” projecting on HBCs (Holbrook, Szumowski et al. 1995) and surprisingly 
they possess primary cilia that seem to be critical for the activation of the 
regenerative capacity (Joiner, Green et al. 2015). 
According to their name, microvillar cells exhibit at the border of their flask-
shaped cell body large, blunt microvilli. Their nuclei lie nearby the external layer 
of the epithelium, while the basal tip is in synaptic contact with the olfactory 
nerve fibers that penetrate the lamina propria (Moran, Rowley III et al. 1982). 
The basement membrane of the olfactory epithelium is generally sharp and 
homogenous, lying beneath the undersurface of epithelial cells.  The lamina 
propria encloses numerous olfactory nerve fascicles and sub-epithelial olfactory 
glands (Bowman’s glands) which secrete mucus into ducts terming on to the 
epithelial surface (Polyzonis, Kafandaris et al. 1979). It also contains some 
pigment cells, lymphoid cells and a rich plexus of blood capillaries. Deeper, there 
is a plexus of large veins and numerous lymphatics. (Krstic 2013). 
The Bowman’s glands are branched tubule-alveolar structures confined under the 
olfactory epithelium (Nakashima, Kimmelman et al. 1984). They secrete into the 
epithelial surface through narrow, vertical ducts releasing defensive substances, 
lysozymes, lactoferrin, Immunoglobulin A (IgA) and sulphated proteoglycans. 
However, the primary function of mucus is to bathe the olfactory cilia in order to 
solubilize and facilitate the diffusion of the odorant molecules and thus their 
detection from the olfactory receptor proteins (Krstic 2013). 
Indeed, the 10-20 elongated terminal cilia emerging from the dendritic knob are 
the cellular compartment of the olfactory neurons where the sensory function 
resides, conferred by the olfactory receptor proteins exposed in their membrane 
surface (Buck and Axel 1991). 
The olfactory cilia present in the ONs have a (9 + 2) microtubule configuration 
that is normally found in motile cilia. Nevertheless, they lack the dynein arms 
required for movement and thence are rendered immotile. They form an 
intertwined mat in order to augment the available surface of the OE for odorants 
by over 40 folds enhancing the global detection capability (Menco 1984) (Jenkins, 
McEwen et al. 2009). 
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The structural framework of the cilia is made up of long α- and β-tubulin strands 
dimers, composing the ciliary axoneme. In this context, the microtubular 
backbone affords the route for molecular motors, such as kinesins, to transport 
cargo inside and outside of the cilium (Jenkins, McEwen et al. 2009) 
Looking more deeply at the olfactory signal-transduction mechanism, we can say 
that it begins when an odorant interfaces with the binding site of an olfactory-
receptor.  In humans, the olfactory receptors genes represent the largest gene 
family of G protein-coupled receptors. These receptors share a 7-transmembrane 
domain structure with many neurotransmitter and hormone receptors (Berghard 
and Buck 1996) (Buck and Axel 1991). An odorant, to be bound by the receptor 
proteins, must be sufficiently volatile and soluble so that some of its molecules 
may foremost reach the surface of the olfactory epithelium and then dissolves in 
the mucous film coating the binding sites. 
In the olfactory epithelium there are as many as 1000 different odorant-binding 
proteins (OBP) whose function is to concentrate and transfer the odorant 
molecules to the receptor proteins (Buck and Axel 1991). 
A single odor, in the recognition process, is broken down into its various 
detectable components, and each of them is complementary to the binding sites of 
one discrete receptor. This mechanism allows that each odorant element 
corresponds to only one type of receptor, among the thousands existing in the 
epithelium. Therefore, the same receptors could be activated from different scents 
that contain common odorant components (Berghard and Buck 1996) (Buck and 
Axel 1991). 
Any receptor protein is coupled to a Guanine nucleotide-binding protein (G-
proteins), which is activated when the odorant molecule is recognized by the 
corresponding olfactory receptor binding site. This event triggers the signal 
cascade leading to cyclic adenosine monophosphate (cAMP) intracellular 
reactions, which in turn induce the Na+ channels to open. As a consequence of the 
related ion movement, neuronal depolarization generates action potentials 
propagated along the axon up to the olfactory bulbs (Buck and Axel 1991).  
About 25.000 axons of olfactory neurons converge and establish synapses with 
each of the 2.000 glomeruli contained in the input layer of one of the two 
37 
 
olfactory bulbs. The glomeruli are rounded structures that receive input only from 
olfactory neurons expressing a particular receptor protein gene so that the odorant 
code corresponds to a glomeruli topological map (Buck and Axel 1991). 
At this level, the mitral and tufted cells of the olfactory bulb send their axons 
through the lateral olfactory tract, linking to the secondary olfactory structures 
(i.e. the anterior olfactory nucleus, the piriform cortex, the medial amygdala 
nuclei, the peri-amygdaloid cortex, and the entorhinal cortex). Then, from the 
above-mentioned structures, fiber connections project to associated neocortical 
areas (tertiary olfactory structures) such as the orbitofrontal cortex and the anterior 
insula. In addition, it is important to mention that functional imaging recordings 
revealed that many other brain areas are activated by olfactory stimuli without a 
direct anatomical link to primary olfactory areas. For example, the pathways also 
include the cerebellum, which seems to have a role in motor control of olfaction 
(Freiherr, Wiesmann et al. 2013)(Welge-Lüssen and Hummel 2004). 
 
Fig. 4 Schematic representation of the anatomy organization of the peripheral 
olfactory system.  
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1.7 Olfactory neuroepithelium: methodological approaches and 
application tools 
 
Given the convenient accessibility of its location,  its inherent regenerative 
capacity and tight connection with the CNS,  the olfactory epithelium and related 
neurons have caught the scientific community’s attention since the mitotic activity 
in the basal cells of the olfactory epithelium of adult mice was first reported 
eighty years ago (Nagahara, 1940). Subsequently, regeneration of olfactory 
sensory neurons was observed in monkeys after toxic damage (Schultz, 1941). 
Scientific interest was directed at understanding not only the intriguing 
physiology of the olfactory system, but also cellular components, including cell 
culture, in order to exploit its unique neurogenic properties  both from a 
diagnostic and a therapeutic perspective (Takagi, 1971, Graziadei, 1973, J. 
Attems, 2015, Choi and Goldstein, 2018). 
 
1.7.1 Culturing olfactory neurons 
 
Since the scientific community realized the neurogenesis potency of the olfactory 
neuroepithelium, many efforts have been made to exploit it in order to establish in 
vitro cell systems and different results have been achieved (Moulton, Celebi et al. 
1970, Smart 1971, Graziadei and Graziadei 1979, Whitman and Greer 2009, 
Brann and Firestein 2014).  
Therefore, the scientific research on this topic directed towards cell culture 
technology development, initially using late gestation embryos of rodent model 
for cell-handling assays (Chuah and Farbman 1983, Calof and Chikaraishi 1989) 
and then manipulating the olfactory tissue of newborn rats (Gonzales, Farbman et 
al. 1985, Pixley and Pun 1990). 
At first, Pixley and Pun ascertained the neuronal nature of rat olfactory cells in 
culture assessing their electrophysiological functionality through recordings of 
electric currents, which were elicited via action potentials evoked by odorous 
stimuli. Further evidence of their neuronal phenotype was provided by 
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immunostaining of neuron-specific proteins: neuron-specific enolase, 
microtubule-associated protein 2, tau protein and synaptophysin (Pixley and Pun 
1990). 
Unfortunately, the cells obtained with this in vitro method could not complete 
their maturation, as indicated by the lack of immunodetection of the olfactory 
marker protein (OMP), which is exclusively expressed in mature olfactory 
neurons (Keller and Margolis 1975, Farbman and Margolis 1980, Miragall and 
Graziadei 1982). 
However, Pixley and Grill developed a new culture system seven years later, 
plating olfactory cells from adult rat nasal mucosal tissue onto a feeder layer of 
newborn rat cortical glia (astrocytes) in serum-free conditions. This novel 
technique, which mimicked a previous strategy with olfactory bulb explants as 
culture substrate (Chuah and Farbman 1983), enabled them to obtain in vitro 
mature olfactory neurons, as confirmed by the OMP immunolabelling (Grill and 
Pixley 1997). Although the physiological function of OMP is not yet fully 
understood (Nakashima, Nakashima et al. 2019), it plays a crucial role in the 
olfactory signal transduction (Buiakova, Baker et al. 1996). In addition, it is 
widely accepted as a marker of mature ONs, even though OMP is also detectable 
in some non-olfactory tissues, which are not classified as classical chemosensory 
(Kang, Kim et al. 2015). 
In the following years, the in vitro methodology made important progress, not 
only in the propagation and differentiation (Liu, Shields et al. 1998)(Cunningham, 
Manis et al. 1999), but also in the short-time maintenance (Vargas and Lucero 
1999) of primary olfactory neurons odorants-responding.  
An important study on the improvement of the culture technique using mice 
olfactory neurons fed onto a cortical astrocytes layer, described a significant 
enhancement of the survival rate and viable cell density in such conditions. In the 
same study, the authors reported the immunodetection of novel neuronal markers 
such as β-tubulin III, NCAM (Neuronal Cell Adhesion-Molecule, CD56) and 
GAP-43 (Growth Associated Protein 43) (Chen, Dadsetan et al. 2008). Moreover, 
the mice cells, which had been plated following the aforementioned protocol, 
completed their maturation process exhibiting the expression of olfactory neuron-
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specific markers like OMP, Golf (an olfactory neuron specific-G protein) (Jones 
and Reed 1989), AC3 ( Adenylate cyclase 3) and CNGA2 (Cyclic Nucleotide 
Gated Channel Subunit Alpha 2) (Chen, Dadsetan et al. 2008). 
Subsequently, research turned its focus on the maintenance and identification of 
the stem and progenitors’ lineage in culture. In fact, it was just known that the 
olfactory mucosa comprehends cells differentiated at diverse levels originated 
from neural stem cells, which mature as glial or neuronal cells under the influence 
of specific growth factors, also in in vitro condition (Goldstein, Fang et al. 1998, 
Sicard, Feron et al. 1998, Murrell, Féron et al. 2005, Guo, Packard et al. 2010, 
Chen, Tian et al. 2014). 
A detailed protocol to isolate stem cells from rodent or human olfactory 
epithelium has recently been published in the peer-reviewed scientific video 
journal JOVE (Girard, Devéze et al. 2011). Nowadays, culturing mice olfactory 
cells is a well-implemented and sound in vitro methodology for neuroscientific 
cellular studies (Gong 2012, Georgiou, dos Reis et al. 2018, Kurtenbach, Goss et 
al. 2019). 
Despite this, the capacity of culturing human samples is far lower compared to the 
results obtained in the mice model. 
In a pivotal study on human, Wolozin and coauthors cultured, for the first-time, 
olfactory epithelium samples, which had been collected postmortem from 
cadavers (Wolozin, Sunderland et al. 1992). Some years later, olfactory cultures 
were obtained from human embryonic tissue (Vannelli, Ensoli et al. 1995). Soon 
after, researchers designed olfactory culture systems from ex vivo human samples 
(Murrell, Bushell et al. 1996, Féron, Perry et al. 1998), but it was only in the 21st 
century that the methodology of culturing olfactory cells from living subjects 
became feasible (Gomez, Rawson et al. 2000, Hahn, Han et al. 2005, Borgmann-
Winter, Rawson et al. 2009) (Tanos, Saibene et al. 2017). 
Despite great efforts, the results of propagating in vivo human olfactory neurons 
from isolated adult olfactory epithelium cells have been modest in terms of 




For example, in the pioneering study by Féron et al. human nasal explants had a 
50% efficacy of producing viable culture, and only 50% of this (25% in total) 
resulted in neurons outgrowth after stimulation with the factor FGF2 (Feron al. 
1998). 
However, fascinating strategies exploiting the differentiation capability of the 
olfactory progenitor cells have been designed to obtain commitment of mature 
neuronal cells. This approach has been implemented mainly in regenerative 
medicine, such as repair therapies after spinal cord injury (Feron, Perry et al. 
2005), and as diagnostic tool for psychiatric and neurodegenerative brain 
disorders, like schizophrenia (McCurdy, Féron et al. 2006, Evgrafov, Wrobel et 
al. 2011, Idotta, Tibaldi et al. 2019) and PD (Matigian, Abrahamsen et al. 2010). 
Lastly, the culturing methodology has been employed also in pharmacology 
strategies for PD treatment using a trans-differentiation method in dopaminergic 
neuron-like cells (Alizadeh, Kamrava et al. 2019, Chabrat, Lacassagne et al. 
2019). 
 
1.7.2 Olfactory biopsies 
 
The initial attempts to perform human olfactory mucosa biopsies have been made 
for electron microscopy analysis in anatomy studies (Douek, Bannister et al. 1975, 
Polyzonis, Kafandaris et al. 1979). It was only in 1982 that a detailed protocol 
was published and through which, using a properly developed instrument and 
technique, it was possible to perform a safe biopsy of the olfactory epithelium in 
living human being (Lovell, Jafek et al. 1982). Since then, the technique has been 
continuously developed (Garcia, Rossaneis et al. 2020) for the evaluation of 
olfactory diseases and dysfunctions, as well as for scientific research intents in 
human, given the fact that olfaction is not adversely affected by this procedure if 
correctly performed (Lanza, Deems et al. 1994). Other applications of the biopsy 
technique included studies of olfaction in aging (Trojanowski, Newman et al. 
1991, Paik, Lehman et al. 1992), the effects of drugs and pollutants (Dalton, Jaen 
et al. 2010, Sammeta and McClintock 2010, Werner, Nies et al. 2018) and the 
evaluation of therapeutic regimens for olfactory disorders(Jafek, Murrow et al. 
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2002). Despite the valuable information obtained with this technique, this never 
became a routine procedure because of its invasiveness and the pain that it causes 
to the subject, but rather is considered a research practice performed with extreme 
caution and discretion in specific cases. 
Taking advantage of the minimum area of tissue which is necessary to obtain a 
whole intact piece of olfactory mucosa and considering that it is suitable for 
immunohistological examinations, biopsies both in human and in animal models 
have been performed to attain immunophenotypic characterization. In this regard, 
an investigation on mice biopsies identified the olfactory neurons with the general 
neuronal marker PGP 9.5 (Protein gene product-9.5), a neuronal marker selected 
also in the analysis performed for this thesis. In the same samples, instead, the 
globose and horizontal basal cells were characterized on the grounds of the 
different levels of Sox2/Pax6 (Sex determining region Y-box-2/Paired box-6) and 
Cytokeratin 14 respectively, while the neuronal progenitors showed a modulation 
of Mash1 (Mammalian aschaete scute homolog-1) and Neurog 1/NeuroD 1 
(Neurogenin-1/Neurogenic differentiation factor-1)(Guo, Packard et al. 2010).  
Very recently, harvested biopsies of olfactory mucosa have been used for the at-
the-state-of-the-art gene expression analysis through single-cell RNA sequencing, 
resulting in the cellular profiling of proteins selected also for the phenotypic 
characterization conducted and depicted in this thesis (Section 4.1), like the 
neuronal marker TUJ-1 and the OMP (Durante, Kurtenbach et al. 2020). 
As described in Section 1.6, the olfactory mucosa lies also in the middle turbinate 
(Leopold, Hummel et al. 2000), and its biopsies contain viable neural progenitor 
cells capable of generating neuronal cell cultures. For these reasons, a technically 
simpler biopsy of the middle turbinate can be applied to propagate in vitro neural 
progenitor cells (Wrobel, Mazza et al. 2013). From the same area, it is also 
possible to attain precious sampling of the olfactory mucosa by the innovative and 




1.7.3 Olfactory brushing in the diagnosis of brain disorders 
 
Olfactory brushing (OBg) is a novel and non-invasive procedure for sampling 
olfactory mucosa (OM) from the middle turbinate (Leopold, Hummel et al. 2000). 
Originally, we showed that OM sampling has a diagnostic application in human 
prion disease. Indeed, OM samples obtained from patients suffering from 
Creutzfeldt-Jakob Disease (CJD) and tested with the real-time quaking-induced 
conversion (RT-QuIC) assay provided a diagnostic accuracy of nearly 100% 
(Orrú, Bongianni et al. 2014).   
In this thesis study, we have used the aforementioned procedure, described in 
detail in Section 3.4, in order to obtain all the precious OM samples both from the 
healthy subjects of control and the synucleinopathies patients.  
44 
 
1.8 Novel prion and prion-like diagnostic in vitro assays 
 
Regarding the analytical tests employed in this thesis for the study of the prion-
like seeding activity of the α-synuclein, we implemented an in vitro assay on the 
ground of the RT-QuIC detection system for prion aggregation.  
 
1.8.1 Real-time quaking-induced conversion  
 
The real-time quaking-induced conversion (RT-QuIC) reaction is an analytical 
technique developed through the combination of the base of the assay designed by 
Kocisko and colleagues (Kocisko, Come et al. 1994) and features of the Amyloid 
Seeding Assay (ASA) designed by Colby and colleagues (Colby, Zhang et al. 
2007).  
RT-QuIC was described for the first time in 2010 as an original technique to 
detect a minimum quantity of PrP
Sc
 (Atarashi, Satoh et al. 2011) (Wilham, Orrú et 
al. 2010). 
Initially, the technique uses a recombinant PrP (rPrP) as substrate for the 
conversion reaction. Indeed, it exploits the ability of PrP
Sc
 to induce the 
misfolding PrP
C
 so that it aggregates forming PrP
Sc
 fibrils.  
In particular, any PrP
Sc
 present in the sample mixture binding the recombinant 
substrate induces a conformational change resulting in the formation of fibrils. 
The mechanism for generating these structures is defined as the lag phase and 
may be necessary for up to 30 hours because it evolves. In the following phase, 
the fibrils formed start to aggregate and in turn bind, thioflavin T, finally emitting 
fluoresce.  
The RT-QuIC reaction is monitored in real-time because of the presence of 
Thioflavin T (ThT) in the buffer, which is an amyloidotropic fluorescent dye. 
During the RT-QuIC reaction, ThT binds to the amyloid and amyloid-like fibril 
species generated by the prion seeded misfolding of the rPrP substrate.  
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Actually, the RT-QuIC mixture with the addition of biological samples is loaded 
in a 96-wells plate, and then the reaction is triggered following several 
intermittent shaking cycles at constant temperature incubated in a plate-reader. 
The advancement of the reaction is revealed in real-time by the detection of the 
fluorescence emitted from ThT bound to amyloid structures. The kinetics of the 
ongoing aggregation is monitored and its graphical representation describes a 
characteristic sigmoidal curve. (Wilham, Orrú et al. 2010) (Atarashi, Sano et al. 
2011).  
Currently, the RT-QuIC assay has been proposed as the first specific in vivo 
diagnostic test for sporadic CJD (sCJD) (Atarashi, Sano et al. 2011). 
Still, Orrù et al. (Orrú, Groveman et al. 2015) achieved an improvement of the 
technique in the analysis of the cerebrospinal fluid (CSF) some years later, the so-
called second-generation RT-QuIC for CSF (IQ-CSF) assay which introduced a 
truncated form, proteinase K-sensitive, of hamster recombinant PrP (rPrP
sen
, aa 
90–231) as substrate and changed few experimental conditions. The results 
obtained with the IQ-CSF assay showed higher analytical and diagnostic 
sensitivity, reducing testing times (Bongianni, Orrù et al. 2017). 
Moreover, our research group designed a protocol for RT-QuIC analysis on 
olfactory mucosa samples obtained by nasal brushing. This method has proved to 
have a comparable specificity and enhanced sensitivity if compared with CSF 
analysis, making an important step further in the intravital diagnosis of the prion 
diseases. (Orrú, Bongianni et al. 2014). 
 
1.8.2 Alpha-synuclein seeding activity detection 
 
Recently, RT‐QuIC technology has been exploited for a novel assay able to 
detect, with high sensitivity and specificity (95‐100%), small amounts of α‐
synuclein aggregate in CSF (Fairfoul, McGuire et al. 2016) (Shahnawaz, Tokuda 
et al. 2017) (Groveman, Orrù et al. 2018) (Sano, Atarashi et al. 2018). 
However, this test has thus far only been assessed in definite clinical cases and/or 
by the classical neuropathological examination confirmed cases, despite the 
clinicians’ requests to obtain indications for the discrimination of the uncertain 
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cases between PD and the various forms of atypical parkinsonism (AP) (van 
Rumund, Green et al. 2019). 
Preliminary studies showed that a significant percentage of MSA and PD 
olfactory mucosa samples obtained through the nasal brushing procedure we 
designed, gave a positive RT-QuIC outcome for the α-synuclein seeding activity 
with high efficiency (De Luca, Elia et al. 2019).  
Interestingly, also some samples of CBD and PSP patients clinically diagnosed 
resulted in RT-QuIC positive assay (Shahnawaz, Tokuda et al. 2017). 
The TEM analysis of the final α-synuclein real-time quacking-induced conversion 
(α-syn RT-QuIC) products obtained from MSA and PD samples showed their own 
structural characteristics eventually making the identification of the starting 
pathology possible, using this discrimination approach (De Luca, Elia et al. 2019). 
The aforementioned study demonstrated the presence of molecular species with α-
synuclein seeding activity in the olfactory mucosa samples of patients suffering 
from diverse synucleinopathies (PD and similar neurodegenerative 
parkinsonisms).  
On the basis of these results, the combination of CSF and OM α-syn RT-QuIC 
tests may be a feasible strategy to improve the global diagnostic accuracy of these 




2. AIMS OF THE THESIS 
 
This study has been designed and conducted in order to pursue the following 
aims: 
 1) the acquisition of “normative values” of olfactory-related proteins in the nasal 
mucosa, collected by OBg procedure;  
2) the definition of the constitutive expression patterns of the major NDs-
associated proteins in the olfactory neuroepithelium of healthy subjects;  
3) the description of the α-synuclein expression patterns in patients with 
synucleopathies;  
4) the comparison between the immunocytochemical results of α-synuclein 




3. MATERIALS AND METHODS 
 
3.1 Laboratories and clinics 
 
All laboratory work included in this thesis has been done in the Neuropathology 
Laboratory of  “Policlinico G.B. Rossi” until May 2019, then moved to the 
Research Centre LURM (Laboratorio Universitario di Ricerca Medica) of the 
University of Verona. Some other experiments have been carried out in the 
laboratory directed by Prof. Mario Buffelli at the Physiology Section of the 
University of Verona. The microscopy confocal acquisition has been run at CPT 
(Centro Piattaforme Tecnologiche) of the University of Verona. 
Following informed consent, the olfactory mucosa samples were executed by Dr. 
Luca Sacchetto, otolaryngologist at the Otorhinolaryngology Clinic of 
“Policlinico G.B. Rossi” and at “Ospedale Civile Maggiore” in Verona.   
Part of the OM samples from patients have been collected at the Department of 
Neurology, Innsbruck Medical University. Other OM samples came from “Clinica 
Neurologica e di Neuroriabilitazione” of “Azienda Sanitaria Universitaria 
Integrata di Udine”, and from “Unità Operativa Clinica Neurologica” of “Azienda 
Ospedaliera Universitaria San Martino” in Genova. 
All the other OM samples came from “UOC di Neurologia” of “Azienda 




3.2 Healthy subjects recruitment 
 
Thirty healthy volunteers underwent nasal swabbing. These included 15 males 
(mean age: 50,4 years; range: 22-78 years) and 15 females (mean age: 54,2 years; 
age range: 19-79 years).  Exclusion criteria were determined by the presence of 
pathology affecting the olfactory function (e.g., recent head trauma, rhinitis or 
chronic sinus infection, diabetes, stroke, history of smoking/alcohol). Olfactory 
swabbing was performed following the approval of the Ethical Committee of 
University Hospital of Verona (Prot.n.28917 June, 15
th
, 2012). Olfactory mucosa 
sampling was performed after written informed consent. 
 
3.3 Patients recruitment  
 
The synuceleinopathies patients have been recruited by Prof. Gianluigi Zanusso, 
neurologist (“UOC di Neurologia” of “Azienda Ospedaliera Universitaria 
Integrata Verona”), by Dr. Ambra Stefani (Department of Neurology, of the 
Innsbruck Medical University), by Francesco Janes (“Clinica Neurologica e di 
Neuroriabilitazione” of “Azienda Sanitaria Universitaria Integrata di Udine”), and 
by Prof. Flavio Nobili (“Unità Operativa Clinica Neurologica” of “Azienda 
Ospedaliera Universitaria San Martino” in Genova). Each patient gave informed 
consent after the explanation of the purpose of the research and the methodology 





3.4 Olfactory brushing procedure 
 
Olfactory mucosa (OM) samples were obtained by the olfactory brushing (OBg) 
procedure. It consists of nasal brushing sampling using a flocked swab (Copan 
Flock Technologies, Italy), which is oriented through the optical guide of a rigid 
endoscope (Fiberscope Storz 0°) into the nasal vault towards the lateral wall of the 
olfactory cleft in order to reach the olfactory epithelium. The use of the endoscope 
ensures that the collection occurs in the neuroepithelium area at the level of the 
medial face of the middle turbinate (Leopold, Hummel et al. 2000). If necessary 
and requested by the subject, the ENT specialist performing the brushing could 
administer a vasoconstrictor (NTR, nasal drops 15 ml: Phenylephrine, 
Thenyldiamine, Benzalkonium chloride; Teofarma Srl, Italy) to make the nostrils 
more accessible and the swabbing even more comfortable. The sampling, where 
possible, was taken in both nostrils. This simple procedure, correctly performed, 
is rapid, non-invasive, inexpensive and can be repeated several times producing 
minimal pain or discomfort to the subject. For each swab provided, we collected 1 
million living cells on average.    
 
3.5 Olfactory mucosa samples processing  
 
The first swab performed from each nostril was directly immersed after the 
procedure in a 15 ml Falcon tube containing the fixative Diacyte (Diapath S.p.a., 
Italy). The second swab instead was immediately conserved in a Falcon tube half-
filled with Saline.  
This protocol, observed for each subject, allowed us to allocate the first samples 
for the immunocytochemistry analysis because the cellular components contained 
in it possess a better-preserved morphology and lower chance of blood traces. The 
following samples collected were commited to the biochemical and molecular 
biology assays. 
The swabs immediately immersed in the Diacyte tube after the sampling 
procedure were left in the fixative solution at least 30 minutes at room 
temperature. After the fixation, a brief treatment (10-15 minutes at room 
51 
 
temperature) with the mucolytic CytoRich Red (Diapath S.p.a., Italy) ensured the 
removal of nasal and other debris and so the cells were recovered vortexing the 
swab. Then, the samples were centrifuged at 1800 rpm and the resulting pellet 
was washed with 1X PBS buffer. The cells, from the pellet, were distributed 
homogeneously in the 1X PBS solution and counted with the Automated Cell 
Counter (Countess™ II FL; AMQAF1000; Invitrogen). Thus, the appropriate 
amount of cells was loaded in dedicated CYTOFUNNELs (Thermo Fisher 
Scientific, Italy) and then placed on cytological slides by the proper 
cytocentrifuge (CYTOSPIN IV, AHSI, Italy). 
As a result, the cytological slides prepared by following the passages described 
above were immediately ready for the immunocytochemistry analysis, or 




In this thesis, the indirect immunofluorescence staining technique has been used 
for the revelation of the primary antibodies binding. This technique exploits a 
fluorochrome-labeled secondary antibody which recognizes the IgG domain of the 
bound primary antibody. 
The first step of the immunofluorescence protocol was the incubation of the 
cytological slides for 1 hour at room temperature with a blocking solution 
containing a mild permeabilization agent (5% of normal serum from the same 
animal species in which the secondary antibodies are raised; 0,3% of Triton™ X-
100; in 1X PBS). Afterwards, the primary antibodies (abs used for the phenotypic 
characterization are listed in Table 1, instead the abs used as neurodegeneration 
markers in Table 2) diluted in a buffer containing 1% of bovine serum albumin 
and the same permeabilization agent (1% of BSA, 0.3% Triton™ X-100; in 1X 
PBS), were incubated over the spots of the cytological slides inside a humid 
chamber overnight at 4°C. After three washings with 1X PBS, which lasted ten 
minutes each, the secondary antibodies Alexa Fluor-conjugated (Life 
Technologies, Carlsbad, CA, USA) diluted (1:1000) in the same solution of the 
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primary abs, were incubated on the microscope slides in the humid chamber, for 
one hour at room temperature.  
Nuclear counterstaining (1:2000) was supplied using 4′,6-diamidino-2-
phenylindole (DAPI) diluted 1:2000 in 1X PBS for 5 minutes after three washings 
in 1X PBS for ten minutes each. 
Lastly, glass coverslips were mounted on the microscope slides with ProLong 



























































































Table 2 Primary antibodies used to identify the expression patterns of the major 
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Images of nasal olfactory mucosa preparations were acquired by a confocal 
inverted Leica TCS SP5 AOBS microscope (Zeiss, Milan, Italy), using a 40x 
(1.25 NA) and a 63x (1.25 NA) oil objectives. Images were saved as .tiff files; 
brightness and contrast were adjusted using the Leica Application Suite Advanced 
Fluorescence (LAS AF) Software (Leica-Mycrosystems, Wetzlar, Germany), 
ImageJ (NIH, Bethesda, MD, USA) or ImarisX64 7.2.1(Bitplane AG, Zurich 
Switzerland). 
 
3.8 Alpha-synuclein RT-QuIC on olfactory mucosa samples 
 
3.8.1 Olfactory brushing samples processing for α-syn RT-QuIC   
 
Following nasal swabbing, one or two swabs were immersed in a 5 ml tube 
containing 0.9% saline and finally sealed. Tubes from each patient were labeled 
with a code, stored at 4°C for α-synuclein real-time quacking-induced conversion 
(α-syn RT-QuIC) assay. Cellular material was dissociated from the brush by 
vortexing the tubes for one minute at room temperature. After removing the brush 
from the tube, the cell suspension was centrifuged at 2000×g at 4°C for twenty 




3.8.2 Expression and purification of recombinant human α-
synuclein 
 
Recombinant α-synuclein was expressed and purified from the periplasmic 
fraction as reported (Bongianni, Ladogana et al. 2019). Briefly, wild-type human 
α-synuclein cDNA was cloned in the pET-28a plasmid (Novagen) and 
transformed into Escherichia coli BL21 (DE3). Cell cultures (1 L) were grown at 
37 °C to an OD 600nm of 0.3–0.4 and the expression was induced with 0.1 mM 
isopropyl b-D-1-thiogalactopyranoside (IPTG) for 5 h. Cells were collected by 
centrifugation, re-suspended in 100 ml of osmotic shock buffer (30 mM Tris–HCl 
pH 7.2, 40% sucrose, 2 mM EDTA) and incubated for 10 minutes at room 
temperature. The cells were centrifuged at 12000 rpm, resuspended in 90 ml of 
cold water with 37.5 ul of saturated MgCl2 solution and, after five minutes 
incubation on ice, centrifuged again. The supernatant containing the periplasm 
proteins was boiled for fifteen minutes and cleared by centrifugation. The soluble 
fraction, enriched in α-synuclein, was subjected to ammonium sulfate 
precipitation followed by extensively dialysis against 20 mM Tris–HCl, pH 8.0. 
Further purification of α-synuclein was performed by anion exchange 
chromatography loading the sample on a Q-Sepharose column (GE Healthcare) 
equilibrated with the same buffer and eluted with a 0–500 mM linear gradient of 
NaCl. The purity of α-synuclein was checked by SDS-PAGE. The protein was 
then dialyzed against 10 mM Sodium Phosphate buffer pH 7.4 and stored at -80 




3.8.3 Alpha-synuclein RT-QuIC assay  
 
α-synuclein real-time quacking-induced conversion (α-syn RT-QuIC) test has 
been set up using definite cases of patients with PD, Lewy body dementia (LBD), 
and MSA as reported (Bongianni, Ladogana et al. 2019). 
OM samples were thawed and a disposable inoculating loop (Fisherbrand) was 
dipped into the pellet to transfer approximately 1 to 2 μl of the pellet into a tube 
containing 120 μl PBS. The latter tube was sonicated until the pellet was 
dispersed. For each test, two microliters of diluted OM sample were plated in 98 
µl of Reaction Buffer composed of 100 mmol/L phosphate buffer (pH 8.2), 
10 μmol/L thioflavin T (ThT), and 0.05 mg/mL human recombinant full‐ length 
(1–140 aa) α‐ synuclein. The plate was sealed with a plate sealer film (Nalgene 
Nunc International) and then incubated at 30°C in a BMG FLUOstar Omega plate 
reader with cycles of 1 min shaking (200 rpm double orbital) and 14 min rest.  
ThT fluorescence measurements (450 +/- 10 nm excitation and 480 +/- 10 nm 
emission; bottom read) were taken every 45 min. Four replicate reactions were 
tested for each sample. The test was considered positive when the reaction 
occurred in 2 out of 4 wells. For the normalization of the curves, a baseline value 
was calculated for each sample, when the lag phase reaches the lowest relative 
fluorescence units (rfu) values, i.e. between 15 and 17 hours. A positive response 
was defined as a value of > 3 SD above the baseline average of all samples, which 
is 100000 rfu. This value was calculated as > 3 SD above the average of all the 
lowest rfu values observed in the lag phase for each sample (i.e. the average 
between 15 and 17 hours). For sensitivity determinations cut-off time was 
assessed at 80 hours, based on the results obtained in the definite cases, in order to 





4.1 Phenotypic characterization of the epithelial cellular samples 
 
The samples have been primarily analyzed looking at the detection of the 
phenotypic markers directed towards neuronal olfactory cells. This step was 
important to ensure that the cellular collection had been made in the olfactory 
region. The following markers were used: olfactory marker protein (OMP) and 
neuron-specific class III β-tubulin (TUJ-1) and the protein gene product 9.5 (PGP 
9.5). We found that OMP immunoreactivity is mainly intracytoplasmic with a 
homogenous distribution array, while TUJ-1 shows the main filament pattern 
tracking the extension of the neural protrusions coming out from the axonal 
hillock (Fig. 5). It has to be pointed out that some non-neuronal shaped cells 
(probably supporting cells) showed positivity to the OMP antibody. Moreover, we 
examined the expression of Pan-Cytokeratin (PCK), a typical epithelial marker in 
combination with PGP 9.5 (Fig. 6), a cytoplasmic protein in neurons and 
neuroendocrine cells, and then with OMP (Fig. 7).  
PGP 9.5 positivity revealed a coin-shaped figure in the cytosolic apical pole of 
mature and immature olfactory neurons and in some non-neuronal-shaped cells, 
likely supporting cells (Fig. 6). The supporting cells are large and columnar cells, 
different from olfactory neurons whose apical part clearly arrange the dendritic 
knob in the mature cell. The cells we considered immature olfactory neurons 
displayed a weaker dotted PGP 9.5 positivity inside the apical region (Fig. 6, 
asterisk). 
PCK mAb binding all the isoforms of the protein showed a positive signal in all 
epithelial cells, neuronal and non-neuronal (Fig. 6 and Fig. 7). In the neuronal 
components, the staining seemed to be confined to the apical intracytoplasmic 
compartment. In particular, there was a main filamentous cytosolic positivity on 
the superior dendritic projection (Fig. 6) while the non-neuronal cells showed the 
positive signal located on the plasma membrane. Lastly, the sample 




Fig. 5 OMP and β-tubulin III (TUJ-1) distribution pattern. OMP expression (green) 
is evident in the cytoplasm of olfactory neurons with a granular pattern inside the cell 
body. The TUJ-1 positivity (red) is marked along the neural projections, in particular in 
the axonal hillock, showing the distinctive β-tubulin III filament pattern. DAPI nuclear 





Fig. 6 Distribution pattern of PGP 9.5 and PCK. PGP 9.5 (red) shows a dotted 
positivity in the upper cytosolic region of the neurons (*, square detail). The PCK (green) 
is identified in the cytosolic compartment of the neurons and in the plasmatic membrane 
of the other epithelial cells (arrows). DAPI nuclear staining (blue). Scale bar overview: 20 





Fig. 7 Two different patterns of PCK immunostaining. The distribution for PCK (red) 
depends on the cell: in the neurons (outlined square, panel A), there is a predominant 
filamentous positivity on the superior dendritic projection, from the center level up to the 
cilia boundary (detail in panel B). In the other cells, the expression is distributed on the 
boundary of the cell body, all along the plasma membrane (arrows). DAPI nuclear 









The α-synuclein is an unfolded 140 amino acid protein encoded by the SNCA 
gene and its function is still not completely known. The distribution of the protein 
is ubiquitous but it is mainly expressed at the tips of neurons as a pre-synaptic 
protein. To detect the total expression of α-synuclein in the olfactory samples we 
selected the referenced 4D6 mAb (Lothian, Lago et al. 2019), which is designed 
on the non-modified full-length protein as the immunogen. Indeed, the 4D6 mAb 
binds all the isoforms of the protein, whatever post-translational modification may 
occur. As shown in Fig. 8, the expression pattern of the protein in cells OMP 
positive with non-neuronal shape is around the cellular membrane, while in the 
OMP negative and neuronal shaped ones there is mainly a granular positivity 
inside the cytosol. In particular, the cytosolic α-synuclein deposition is visualized 






Fig. 8 Distribution pattern of α-synuclein. In the neurons, α-synuclein (4D6, red) 
shows a predominant diffused cytosolic thinly granular labeling particularly localized at 
the dendritic knob (outlined square in panel A, arrow on detail in panel B). In the other 
cells OMP positive (green), α-synuclein shows a positivity around the plasmatic 








4.2.2 APP/β-Amyloid  
 
APP gene encodes for the amyloid precursor protein, a transmembrane 
glycoprotein processed through sequential cleavages performed by different 
secretases. Amyloid beta (Aβ) is derived from APP by sequential cleavages of β- 
and γ-secretase. APP is widely expressed in human tissues with great expression 
in the central nervous system (Wang, Gu et al. 2017). 
The 6E10 mAb reacts to residues 1-16 of Aβ and the epitope lies within amino 
acids 3-8 protein. We found that immunoreactivity to the 6E10 mAb is mainly 
localized in the neuronal-shaped cells, TUJ1 positive. It shows a dot-like 
distribution especially in the paranuclear level and at the tips of the cell (Fig. 9). 





Fig. 9 Distribution pattern of APP. In the neurons (TUJ-1 positive, green), APP (red) 
has a focal expression (dot-like) mainly around the nucleus and at the level of the cellular 
tips (outlined square in panel A, details in panel B, arrows). DAPI nuclear staining (blue). 






Tau-protein exists in six distinctive isoforms of different lengths in the human 
nervous system. This protein is a microtubules associated protein (MAP) and its 
function is to interact with tubulin to stabilize the microtubules framework. The 
six tau isoforms are generated from MAPT, the tau gene, through alternative 
messenger RNA (mRNA) splicing. Alternative splicing of exon 10 gives rise to 
three isoforms with three microtubule-binding repeats (3R) each and three 
isoforms with four microtubule-binding repeats (4R) each (Goedert, Spillantini et 
al. 1989). 
Immunostaining with total tau antibody (tau-5 clone) (Puvenna, Engeler et al. 
2016) (Borin, Saraceno et al. 2018) was detected in the neuronal shaped cells with 
a cytosolic localization (Fig. 10, arrows). The expression pattern is intracellular 
with a patch framework along the cell body, probably because the protein is 
associated with the microtubule cytoskeleton in specific cellular districts. 
Interestingly, when we decided to look at the typing of tau isoforms expressed in 
the mucosal samples, we found a positivity for the 4R class in the mature neuronal 
shaped cells. This is remarkably visible within the area underlying the olfactory 
knob (Fig. 11, A, B).  On the other hand, for the 3R tau class, we found a very 
limited detection and the positivity displayed an uneven clustered pattern only in 






Fig. 10 Distribution pattern of tau-5. The total tau protein (tau-5) expression is found 
all along the cell body with particular intensity in the perinuclear region of the cytosol’s 
neurons (outlined square in panel A; detail in panel B, arrows). DAPI nuclear staining 






Fig. 11 Distribution pattern of tau isoforms expression. A and B panels show that the 
tau 4R isoform (green) is mainly localized in the cytosolic upper part of the neuronal 
TUJ-1 positive cells (red), close to the dendritic knob (arrows). Concerning the 3R 
isoform (green), we only found some relatively uneven distributed positive spots in 
rounded cells, likely globous stem cells, negative for the TUJ-1 antibody (C and D 





Transactive response DNA binding protein 43 (TDP-43) is a DNA binding 
protein, originally discovered in a wide-screen investigation for protein factors, 
which is able to bind the long terminal repeat transactive response element of 
HIV-1(Ou, Wu et al. 1995). This protein plays a role in transcription, alternative 
splicing, and messenger RNA (mRNA) stability. Also, it is involved in various 
cellular processes, including apoptosis, cell division, and axonal transport. Under 
physiological conditions, TDP-43 travels between the nucleus and cytoplasm, and 
after a nuclear localization signal, it is imported into the nucleus (Winton, Igaz et 
al. 2008). 
It is reported that TDP-43 beyond neurons, is abundantly expressed in glia, as 
well as in many other cell types (Kawakami, Arai et al. 2019).  
Here immunostaining was detected in the nuclear area and the expression of the 
protein is wide and homogeneous in all the samples analyzed. The resulting 
pattern reveals an intense intranuclear distribution with several positive grains 






Fig. 12 Distribution pattern of TDP-43. The expression pattern of TDP-43 (overview in 
panel A, detail in panel B) is clearly nuclear (arrows) beyond weak staining of the cytosol 
(*). Almost all cells show nuclear positivity. DAPI nuclear staining (blue). Scale bar 




4.3 Evaluation of the α-synuclein expression patterns in 
synucleinopathies patients 
 
We explored the potential differences in the expression pattern of the α-synuclein 
between healthy controls and patients affected by synucleinopathies (Table 3): 
Parkinson's disease (PD), Rapid-eye-movement behavioral disorder (RBD), Lewy 
body dementia (LBD), Multi System Atrophy (MSA).  In some cases, age and 
gender were not available (n.a.) because they derived from a double-blind study. 
The RT-QuIC results are reported in terms of the ratio between the positive wells 
and the total 4 wells tested. Grading values of the immunocytochemistry (ICC) 
analysis are: “negative” (−), “normal” (-/+), “weak” (+), “moderate” (++), 
“strong” (+++). 
Table 3 Demographic profile of the patients with α-synucleinopathies 








1. 2017_1 59 M PD -/+ + 4/4 
2. 2017_2 45 M PD + + 2/4 
3. 2017_3 58 F PD + + 2/4 
4. 2017_4 n.a. n.a. RBD + ++ 0/4 
5. 2017_5 n.a. n.a. RBD +++ +++ 0/4 
6. 2017_6 n.a. n.a. RBD + -/+ 0/4 
7. 2017_7 n.a. n.a. RBD + ++ 0/4 
8. 2017_8 n.a. n.a. RBD -/+ ++ 0/4 
9. 2017_9 n.a. n.a. RBD + -/+ 0/4 
10. 2018_1 73 M LBD +++ + 4/4 
11. 2018_2 75 F MSA + ++ 4/4  
12. 2018_3 n.a. n.a. LBD +++ + 4/4 
13. 2018_4 71 F PD + -/+ 2/4  
14. 2018_5 n.a. M RBD + ++ 4/4 
15. 2018_6 71 M PD  + + 4/4 
16. 2018_7 75 M LBD +++ + 4/4 
17. 2018_8 68 M PD  + ++ 4/4 
18. 2018_9 64 M RBD + ++ 4/4 
19. 2018_10 75 M RBD + ++ 3/4 
20. 2018_11 71 M RBD + ++ 1/4 
21. 2018_12 64 F RBD + +++ 4/4 
22. 2018_13 76 F RBD + ++ 4/4 
23. 2018_14 75 M PD  ++ ++ 4/4 
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24. 2018_15 76 M LBD -/+ -/+ 0/4 
25. 2018_16 67 M LBD ++ +++ 3/4 
26. 2018_17  75 M PD ++ + 4/4 
27.  2018_18 70 M LBD ++ ++ 4/4 
28. 2018_19  n.a. F MSA -/+ ++ 0/4 
29. 2019_1 n.a. F LBD + ++ 4/4 
30. 2019_2 n.a. n.a. LBD + ++ 4/4 
31. 2019_3 n.a. n.a. LBD + + 4/4 
32. 2019_4 n.a. n.a. LBD + ++ 2/4 
33. 2019_5 n.a. n.a. PD ++ +++ 0/4 
34. 2019_6 69 M PD  + ++ 0/4 
35. 2019_7 n.a. M PD ++ ++ 2/4 
36. 2019_8 n.a. n.a. LBD + ++ 0/4 
37. 2019_9 n.a. n.a. LBD ++ + 0/4 
38. 2019_10 n.a. n.a. PD ++ ++ 2/4 
39. 2019_11 n.a. n.a. LBD + ++ 2/4 
40. 2019_12 n.a. n.a. LBD + ++ 3/4 
41. 2019_13 n.a. n.a. PD ++ ++ 0/4 
 
Immunocytochemistry analysis results revealed a differential expression and 
distribution both for the total α-synuclein and the phosphorylated isoform, which 
is more closely involved in the pathology mechanism.  
In particular, Table 4 summarizes the main observed levels of expression 
compared to the healthy controls for each diagnostic group. 
 
Table 4 Summary of the most recurrent α-synuclein expression pattern in the relative 
synucleinopathies’ group 








































PD: Parkinson's Disease, LBD 1: Lewy Body Dementia with pattern 1, LBD 2: Lewy 
Body Dementia with pattern 2, MSA: Multi-System Atrophy, RBD: Rapid-eye-
movement Behavioral Disorder. Grading values of expression: “negative” (−), “normal” 




We also observed distinctive α-synuclein distribution patterns in each pathological 
group in detail, as described below. 
 
4.3.1 Alpha-synuclein expression patterns in PD group 
 
The immunocytochemistry analysis of the total and phosphorylated expression of 
α-synuclein in the olfactory mucosa brushing samples of patients diagnosed as PD 
revealed that both antibodies give quite higher signaling compared to normal 
levels of the controls. In addition, this increased positivity, appeared to be 
proportional in both isoforms. Moreover, even the distribution patterns were 
different from the controls. In fact, the pattern related to the PD group showed the 
presence of the two markers both in the cytosol, particularly inside vesicles at the 
sub-apical level for the phosphorylated form, and in the nucleus. 
 In particular, the 4D6 mAb, which recognizes the total α-synuclein, was found 
throughout the cellular body in a homogeneous manner, especially in the olfactory 
neurons where showed also denser grains in the terminal knob. 
In addition, it seems that in some defined cases the nuclear fraction, lacked the P 






Fig. 13 Representative immunofluorescence (merge) illustrating the characteristic 
expression patterns of the total α-synuclein (red) and the phosphorylated isoform (green) 
in the control group (A, B); and PD group (C, D). DAPI nuclear staining (blue). All the 






4.3.2 Alpha-synuclein expression patterns in LBD group 
 
Regarding the expression of α-synuclein in the LBD group, we observed two 
different expression patterns that may be summarized in two sub-groups: the first 
one (LBD 1) is characterized by enhanced detection of phosphorylated α-
synuclein both in the nucleus and in the cytosol within intracytoplasmic vesicles, 
while the total form was increased with a minor degree.  
In some cases, the intra-nuclear staining showed positivity to both markers with a 
few tiny dots related to 4D6 mAb (Fig. 14). 
The second pattern is characterized by abundant granular deposition of the total 
isoform, which is notably hyper-expressed in the cytosolic compartments. The 
phosphorylated isoform in this sub-group of LBD patients (LBD 2) appears less 
augmented than the other LBD sub-group and well-confined to the apical border 










Fig. 14 Representative immunofluorescence (merge) illustrating the characteristic 
expression patterns of the total α-synuclein (red) and the phosphorylated isoform (green) 
in the control group (A, B), and LBD 1 group (C, D). DAPI nuclear staining (blue). All 








Fig. 15 Representative immunofluorescence (merge) illustrating the characteristic 
expression patterns of the total α-synuclein (red) and the phosphorylated isoform (green) 
in the control group (A, B), and LBD 2 group (C, D, E, F). DAPI nuclear staining (blue). 
All the superior panels (A, C, E) are at 40x, while the panels below (B, D, F) at 60X. 




4.3.3 Alpha-synuclein expression patterns in MSA group  
 
With regard to the two cases of MSA, the immunocytochemical analysis revealed 
a clear increase of the phosphorylated form throughout the sample, unlike the 
form recognized by the 4D6 mAb, which is not very different from the control 
levels.  
Specifically, the phosphorylated isoform was found particularly concentrated in 
the apex of the neuroepithelial cells with some cytosolic vesicles present in the 
sub-apical region. 
The total isoform, albeit less expressed than the other marker, showed a granular 
cytosolic distribution, which had not been observed in the control group. 
In one case, some neuroepithelial cells showed weak P Ser 129 signal also in the 













Fig. 16 Representative immunofluorescence (merge) illustrating the characteristic 
expression patterns of the total α-synuclein (red) and the phosphorylated isoform (green) 
in the control group (A, B); and MSA group (C, D). DAPI nuclear staining (blue). All the 






4.3.4 Alpha-synuclein expression patterns in RBD group 
 
The immunocytochemical analysis of α-synuclein expression in the RBD group 
showed a homogeneous distribution of the grading values: altogether, the 
phosphorylated isoform increased much more than the total form of the pre-
synaptic protein. 
Only one case owned strong hyper-expression for both the markers in an equal 
manner. 
 In general, the P Ser 129 revealed an enhanced expression in the cytosol, 
especially in apical regions, and it was sometimes observed deposited in the 
nucleus. 
As for the 4D6 mAb detection, we observed concomitantly a smaller increase 
characterized by particular distribution featuring a tiny cytosolic pattern lacking 
the intra-nuclear signal. 
It has to be pointed out that the olfactory neurons showed greater cytoplasmic 
expression of the total isoform, compared to the other neuroepithelial cells of the 










Fig. 17 Representative immunofluorescence (merge) illustrating the characteristic 
expression patterns of the total α-synuclein (red) and the phosphorylated isoform (green) 
in the control group (A, B), and RBD group (C, D). DAPI nuclear staining (blue). All the 





4.4 Alpha-synuclein expression patterns in relation to the RT-
QuIC seeding activity in synucleinopathies patients 
 
Lastly, we compared the α-synuclein expression patterns between RT-QuIC 
negative and RT-QuIC positive pathological OM samples. Indeed, the α-syn RT-
QuIC assay has proven to be a specific test and sensitive to reveal the seeding 
activity of the pre-synaptic protein in OE samples. 
We primarily found the phosphorylated a-synuclein isoform in the nucleus of the 
positive samples for the seeding activity (see arrows in Fig. 18). In particular, the 
phosphorylated isoform showed a variable degree of the nuclear detection signal 
within 56,1% (23 out 41) of the total analyzed samples, with a percentage of 
88,4% inside the group of positive cases (23 out 26). 
Differently, the nuclear deposition of the total isoform was observed in the 30,7% 
of the α-syn RT-QuIC positive cases (8 out 26). Moreover, 75% (6 out 8) of these 
last positive samples, showed P-ser-129 in the nucleus with a lower intensity 
compared to the simultaneous nuclear detection of the total α-synuclein. 
On the other hand, we found a nuclear positivity of one of the two markers also in 






Fig. 18 Representative immunofluorescence (merge) illustrating the characteristic 
expression patterns of the total α-synuclein (red) and the phosphorylated isoform (green) 
in the RT-QuIC negative group (A, B), and RT-QuIC positive group (C, D). The arrows 
point to the nuclear localization of the P Ser 129. DAPI nuclear staining (blue). All the 







In this thesis work, we investigated: 
1) first of all, the phenotype of the olfactory cells, especially olfactory neurons 
collected by the olfactory brushing technique in humans; 
 2) secondly, the presence and the related expression patterns of the main NDs-
associated proteins in healthy controls; 
3) thirdly, the α-synuclein expression pattern variations in patients with 
synucleopathies; 
4) lastly, the α-synuclein expression patterns in relation to the α-syn RT-QuIC 
seeding activity results in the same patients. 
Olfactory impairment is recognized as a prodromal symptom in patients with 
neurodegenerative diseases suggesting that the olfactory system and particularly 
the olfactory mucosa represent an intriguing neural tissue for the exploration of 
the mechanisms underlying the neurodegenerative process. 
In this thesis, we showed that the human olfactory neuroepithelium can be easily 
sampled by the olfactory brushing technique, collecting neurons and cells from 
neuronal lineage for morphological and immunocytochemical investigations. 
Olfactory brushing allows gentle collection of olfactory mucosa, it can be easily 
performed, it is non-invasive, non–traumatic and produces minimal pain or 
discomfort. The collected cells show a well-preserved native morphology, 
enabling the recognition of olfactory neurons, characterized by the typical bipolar 




5.1 Phenotypic characterization of the olfactory neuroepithelium 
cells  
 
Since the variety of cells retrieved from each sampling was highly unpredictable 
and the cell typing was unsuitable to be addressed only by the morphology 
analysis, our study firstly aimed at the phenotypic characterization with ensuing 
identification of specific neuronal markers for the ONs. 
OMP was the first discovered marker for ONs (Monti-Graziadei, Margolis et al. 
1978), associated with the olfactory transduction (Albeanu, Provost et al. 2018) 
towards the olfactory bulb. The OMP staining showed the characteristic 
intracytoplasmic localization of the protein (Kream and Margolis 1984).  
However, the positive signal was also detected in some non-neuronal shaped cells 
(probably supporting cells and olfactory neurons not yet mature). This unexpected 
pattern of detection of the OMP was repeatedly observed, using all the different 
antibody clones for the marker, some of which had been also removed from the 
market.  
OMP is widely accepted as a marker of mature ONs, even though its 
physiological function is not fully understood (Nakashima, Nakashima et al. 
2019). In addition, OMP was also detected in some non-olfactory tissues, which 
are not classified as classical chemosensory tissues (Kang, Kim et al. 2015). 
We found that around 30% of the total cells were OMP positive, and they showed 
both neuronal and non-neuronal morphology. Taking into account that, we 
analyzed the OM samples obtained from the middle turbinate, we cannot exclude 
that OMP expression in apparently non-neuronal cells might indicate a 
modulatory paracrine role of these cells on the olfactory function of the ONs. In 
middle turbinate, ONs are unevenly distributed, compared to the ones of the 
mucosal surface covering the lamina cribra. Moreover, the olfactory epithelium in 
humans is not clear-cut from the non-olfactory tissue, whereas in rodents there is a 
marked boundary. In addition, in the airway system, it was showed that ciliated 
cells have chemosensory features (Shah, Ben-Shahar et al. 2009); (Merigo, Benati 
et al. 2012) and, as reported recently in the rat trachea, it is possible that the 
various epithelial cell populations cooperate within an intricated cellular network, 
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each of them with different chemosensory properties (Lasconi, Pifferi et al. 2019).  
Furthermore, because of the extremely dynamic properties of the olfactory 
epithelium, OMP positivity in apparently non-neuronal shaped cells might 
indicate that these olfactory cells did not ultimate their maturation process. 
Indeed, cytological preparation from a heterogeneous epithelium like the olfactory 
mucosa disrupts the architectural integrity of the epithelial surface. In that way, 
the topographical information providing cues regarding the neuronal maturation 
path is lost.  
Furthermore, β-tubulin III (specifically TUJ-1 marker), as already reported in 
previous studies on olfactory biopsies (Holbrook, Wu et al. 2011, Tanos, Saibene 
et al. 2017) (Durante, Kurtenbach et al. 2020), could be considered an efficient 
neuronal marker. 
The marking obtained with the TUJ-1 clone of the β-tubulin III is located mainly 
within the axonal projection, and it is particularly evident on the axonal hillock 
showing a filament pattern. The combination of OMP and TUJ-1, provided 
effective ONs identification is effective and both markers proved useful to focus 
the study of the neurodegeneration-associated proteins on this cell type. 
In addition, we showed that the PGP 9.5, a neural marker, which is commonly 
adopted as a neuronal-specific marker, labeled ONs showing punctuate staining in 
the cytoplasm while other ciliated and tubular cells different from neurons, 
showed rounded staining in the cytoplasmic apical pole. This labeling pattern 
confirms previous comparable results described in adults and developing humans 
(Johnson, Eller et al. 1997) (Witt, Bormann et al. 2009) (Holbrook, Wu et al. 
2011), showing that the respiratory epithelium marker β-tubulin type IV co-
labeled with the PGP 9.5 positive non-neuronal shaped cells. Therefore, we 
cannot exclude that the non-neuronal shaped PGP 9.5 positive cells we found 
might be not yet mature neurons or isolated metaplastic olfactory neurons 
possibly related to subclinical inflammatory status. Also the sustentacular-like 
cells positive to the PGP 9.5 that we found could be cells derived from common 
progenitors to the olfactory neurons, and consequently, they express general 
neural marker as the protein gene product 9.5 (Guo, Packard et al. 2010).   
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In addition, we have characterized the other epithelial cells of the olfactory 
epithelium using a monoclonal antibody (mAb) against all the isoforms of the 
cytokeratin (PCK), which have been proved to be expressed in the olfactory 
epithelium (Witt, Bormann et al. 2009) (Chen, Kachramanoglou et al. 2014) 
(Hahn, Han et al. 2005). We assessed this general epithelial marker in 
combination with marker PGP 9.5 and then with OMP.  
PCK, although it marked nearly all the epithelial cells, showed a different 
distribution pattern depending on the cell lineage, with an intracytoplasmic 
localization in ONs and a plasmatic membrane marking in the supporting cells. In 
fact, the two different cellular classes, derive from the same progenitor originating 
from the horizontal stem cells, then committed in the neuronal or glial direction 
depending on the specific growth factors and differentiation stimuli present 
(Goldstein, Fang et al. 1998, Sicard, Feron et al. 1998). 
Therefore, after this first part of the study, we decided to set and optimize the 
sampling and immunocytochemistry techniques. The achievement of these 
improvements was a prerequisite that allowed us to characterize the phenotype of 
the OM cells recovered by the nasal brushing procedure. In particular we focused 
on ONs, due to the fact that with had lost the the structural overview of the tissue 
and its cytoarchitecture.  
Finally, through the lens of our methodological approach, we could assess the 
health state and the integrity of the OM cellular constituents as if we were taking a 
snapshot of the single cells in the sampling's instant and thus investigate whether 




5.2 Expression patterns of ND-associated proteins in olfactory 
cells of healthy subjects 
 
In the second phase of our study, we evaluated the expression pattern of some 
neurodegeneration-associated proteins, which had been previously investigated 
only in rodents or in a few postmortem or bioptic human studies (Rey, Wesson et 
al. 2018). The physiological production of those proteins which are prone to self-
aggregate represents the condition "sine qua non" for triggering the aggregation 
cascade and the relative pathological pathway. According to  Braak’s "dual hit 
theory" and Doty’s "olfactory vector hypothesis", the basal expression of protein 
with prion-like features in the olfactory epithelium could supply the brain of 
aberrant species via anterograde axonal route (Hawkes, Del Tredici et al. 2007) 
(Doty 2008). Indeed, in some neurodegenerative disorders such as Alzheimer’s 
disease or Parkinson’s disease different studies have shown the presence of Lewy 
neurites, neurofibrillary tangles or β-amyloid deposits in ONs (Crino, Greenberg 
et al. 1995); (Talamo, Rudel et al. 1989); (Trojanowski, Newman et al. 1991); 
(Lee, Goedert et al. 1993); (Funabe, Takao et al. 2013); (Saito, Shioya et al. 
2016). These findings indicate that misfolded species with seeding activity may be 
transported to the olfactory bulb glomeruli where they accumulate and aggregate. 
According to this perspective, it might be difficult to observe the typical 
pathological changes in the ONs, since they undergo a complete recycle every 
three months and this time-course might be not sufficient to carry out the 
aggregation process.  
For these reasons, we decided to investigate the normal expression of 
neurodegeneration-associated proteins in olfactory neurons from healthy subjects. 
This investigation revealed distinctive expressions for each selected protein, 







At present, no comprehensive mapping studies of the normal α-synuclein 
expression have been performed in human whole-brain. The partial investigations 
in the peripheral regions, included in Braak’s theory, had been either conducted in 
the enteric nervous system (Böttner, Zorenkov et al. 2012) or explored the 
pathological forms of the protein (Bloch, Probst et al. 2006). However, in elderly 
healthy subjects, consistent levels of α-synuclein were seen in olfactory brain 
areas (Freer, Sormanni et al. 2016) and only one study evaluated the α-synuclein 
expression in the human olfactory mucosa, showing a positive signal not only in 
basal cells and ONs but also in supporting cells and Bowman’s gland component 
(Duda, Shah et al. 1999). Our results are in line with these previous findings and 
reveal the constitutive expression of α-synuclein in the olfactory epithelium cells. 
In particular, we showed the non-exclusive neuronal expression of α-synuclein in 
the OE, which agrees with the notion that such protein is ubiquitous (Baltic, 
Perovic et al. 2004). The relative distribution patterns described a membrane 
localization in neuronal and non-neuronal cells, while the intracytoplasmic 




APP is a long integral membrane glycoprotein that forms Aβ-peptide after the 
proteolytic secretase cleavage, whose amyloid fibrillar form is the primary 
component of amyloid plaques found in the brains of AD patients. Although the 
native biological role of APP is of obvious diagnostic and therapeutic interest, its 
thorough understanding remains elusive.  
APP has been considered a non-exclusive neuronal protein for more than twenty 
years, but the recent notion regarding its localization claims that it is 
predominantly expressed in the forebrain, in which the olfactory system is 
contained (Corbett and Buss 2014). There are no data available showing the APP 
expression in olfactory structures in humans, whereas it was found in the olfactory 
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bulb of rats beyond various cortical olfactory regions. Unfortunately, the AON 
and the OE were not investigated (Struble, Dhanraj et al. 1998)(Rey, Wesson et 
al. 2018).  
According to the findings in olfactory epithelium biopsies (Arnold, Lee et al. 
2010), we showed the physiological expression of the APP in ONs, displaying a 
dotted cytosolic pattern both at the perinuclear level and within the axonal and 
dendritic terminations. Similar results have been previously reported specifically 




Tau is a microtubule-associated protein (MAP) originally purified from brain and 
recognized for its ability to promote microtubule assembly in vitro (Weingarten, 
Lockwood et al. 1975). A pioneering study on the OE in AD patients conducted in 
1993 showed the expression of tau in the axons of the olfactory neurons during 
their dystrophic transformation (Lee, Goedert et al. 1993). 
The physiological Tau expression has not been evaluated in human olfactory 
structures (Rey, Wesson et al. 2018). Olfactory regions were only explored in rats, 
showing that tau is greatly expressed in ONs and in their axons in the olfactory 
bulb, beyond mitral cells and interneurons (Viereck, Tucker et al. 1989) 
(Schoenfeld and Obar 1994). 
In this thesis, we showed that total tau protein was mainly localized around the 
nuclear compartment and in the apical region of human ONs. Some dotted 
positivity appeared in clustered cells, and such form of the protein may be 
released from the dying neurons or secreted by a physiological mechanism of 
defense to prevent an elevated intracellular concentration of the protein (Perea, 
Llorens-Martín et al. 2018) (Pooler, Phillips et al. 2013). We observed 
sporadically a clear well-compartmentalized concentration of tau in a cytosolic 
organelle, probably Golgi apparatus during the processing preceding the secretion. 
(Mohamed, Desjardins et al. 2017). 
The analysis of tau isoforms typing revealed no detection of 3R isoform, apart 
from some rare positive globous cells, likely stem cells, in line with the notion 
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that such isoform is expressed during developmental stages (Goedert, Spillantini 





Originally TDP-43 was discovered during a wide-screen investigation into 
protein factors having the ability to bind the long terminal repeat transactive 
response element of HIV-1(Ou, Wu et al. 1995). Under physiological conditions, 
TDP-43 travels between the nucleus and cytoplasm, and after a nuclear 
localization signal, it is imported into the nucleus (Winton, Igaz et al. 2008). Even 
if TDP-43 is mainly located in the nucleus, in healthy state, a significant 30% of 
the normal protein can be found in the cytoplasm (Kawakami, Arai et al. 2019) 
and its export is largely driven by passive diffusion (Ou, Wu et al. 1995).  
TDP-43 was identified as the major brain component associated with 
amyotrophic lateral sclerosis (ALS), as well as with frontotemporal lobar 
degeneration (FTLD) (Neumann, Sampathu et al. 2006). Under pathological 
conditions, TDP-43 is discharged from the nucleus and gathers in the cytoplasm 
(Arai, Hasegawa et al. 2006). The translocation into the cytoplasm appears to be 
the result of compromised nuclear transport and solubility of the protein. This 
idea is consistent with the evidence that TDP-43 seeds in the cytoplasm promote 
its mislocalization by affecting nuclear transport and with the presence of 
proteins involved in nucleo-cytoplasm transport in pathological TDP-43 
aggregates (Chou, Zhang et al. 2018). 
At any rate, the neurotoxicity of aberrant TDP-43 has not been completely 
clarified yet. Although the localization of TDP-43 in the cytoplasm is widely 
thought to be the cause of the TDP-43 nuclear fraction loss, some studies 
indicate that there is no correlation between the nuclear depletion and the 
neuronal toxicity, while the presence of cytoplasmic mutant of TDP-43 induces 
the neurodegeneration process  (Kawakami, Arai et al. 2019). 
Interestingly, as it happens with the other ND-associated protein, the 
accumulation of TDP-43 is related to many post-translational modifications, such 
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as hyperphosphorylation, ubiquitination and abnormally cleavage generating C-
terminal fragments (Neumann, Sampathu et al. 2006). Moreover, TDP-43 
inclusions are thioflavin-S positive (Bigio, Wu et al. 2013), suggesting that the 
aggregation occurs in a way that is analogous to amyloid-like fibrils. 
Our analysis of TDP-43 physiological expression in the OE brushing samples 
reveals a widespread production of the protein in the majority of the cells 
collected. Furthermore, the expression pattern of the protein we found is 
consistent with the general typing of TDP-43, showing a preponderant nuclear 
localization of the protein, with weak positive signals in the cytosolic region. 
 
5.2.5 Overall Discussion on the Expression of ND-associated-
proteins in healthy subjects 
 
We have shown for the first time that ONs, express all the marker proteins 
investigated: α-synuclein, APP/β-Amyloid, TDP-43, and tau protein. In addition, 
for some of these proteins, we found a non-exclusive neuronal expression, as for 
the TDP-43 and α-synuclein.  
These findings suggest that, directly or indirectly, the potential contribution of 
ONs and the other olfactory epithelium cells cannot be excluded, from the 
triggering of neurodegeneration processes (Rey, Wesson et al. 2018). In this 
regard, glial and supporting cells of the olfactory tissue and OB could play a 
crucial role in the onset mechanisms of the pathology. The key role of the 
sustentacular cells in the neurodegenerative pathways should be associated with 
the loss of their essential functions in protecting brain structures against external 
insults and in sustaining neurons for proper transduction into the brain. Moreover, 
further pieces of evidence in line with this concept came from several animal 
studies in which the intranasal administration of toxicants produced analogous 
alterations to the pathological signs (Prediger, Aguiar et al. 2012). 
The study of the constitutive expression of the main misfolding-prone proteins in 
healthy human olfactory mucosa represents a very promising research matter. The 
fact that the olfactory neuroepithelium, including not only ONs but also the other 
neighboring cells, is highly exposed to viral and/or toxic/environmental insults, 
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might trigger the protein misfolding in these cells and disrupt the physiological 
interaction of the different cell types, resulting in olfactory signal impairment and 
dysfunction. Misfolded proteins may form early oligomers which might be 
transported through the axonal anterograde pathway to the OB, where they might 
assembly into fibrillary structures and amyloid deposits. In support to this 
hypothesis are the occurrence of smell loss, the pathological involvement of the 
olfactory pathways in the initial stages of the ND, and the evidence that 





5.3 Alpha-synuclein expression patterns in synucleinopathies 
patients 
 
In the further phase of our study, we focused on the exploration of variations in α-
synuclein expression patterns under pathological conditions.  
Thus, we compared the expression levels and the distribution patterns of the α-
synuclein between healthy controls and patients affected by synucleinopathies 
such as Parkinson's disease (PD), Rapid-eye-movement behavioral disorder 
(RBD), Lewy body dementia (LBD), and Multiple System Atrophy (MSA). 
The shreds of the experimental evidence introductory to this investigation derived 
from previous studies in autopsic olfactory epithelium specimens of patients with 
the same disorders as the aforementioned synucleinopathies (Funabe, Takao et al. 
2013) (Saito, Shioya et al. 2016). 
On the other hand, we were aware that in another investigation on OE biopsies 
from patients affected by Parkinson’s disease, Witt et al. have reported no 
histochemical detection of α-synuclein immunolabeling (Witt, Bormann et al. 
2009). Another work preceding the aforementioned studies investigated synuclein 
family proteins in biopsies of patients with various synucleinopathies. The results 
of this antemortem investigation revealed abnormal dystrophic neurites in the OE 
of patients with PD, LBD, AD, and MSA, even though similar detection had been 
observed also in the OE of normal controls (Duda, Shah et al. 1999). 
Our immunocytochemistry analysis showed changes of the expression patterns 
between normal controls and synucleinopathies' patients, both for the total α-
synuclein detected by the 4D6 mAb and for the isoform phosphorylated in Serine 
129 (Ser 129). In this last isoform, the native protein underwent the most relevant 
post-translational modification involved in the pathogenesis mechanisms 
(Fujiwara, Hasegawa et al. 2002). Specifically, we revealed a different 
distribution array for both markers in each synucleinopathies group. Particularly, 
we observed the principal patterns associated with each clinical diagnosis: in the 
PD group, we frequently recognized a parallel increase of expression, from weak 
to moderate, for both α-synuclein isoforms. Besides, we found positive signals of 
the two markers in the nuclear and cytosolic compartments. The variability of the 
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α-synuclein expression inside the PD group could reflect the different stages of 
maturity of the disease in the brain (Covell, Robinson et al. 2017). 
In the OM samples from patients with LBD, we identified two different 
expression patterns. The first one is characterized by a moderate rise of detection 
of the phosphorylated α-synuclein in the nucleus and inside apical vesicles. The 
second pattern is characterized by abundant granular deposition of the total 
isoform in the cytosol, especially in the soma of the ONs. The phosphorylated 
isoform in this subset of LBD patients appears not to have increased and to be 
well-confined in the brush border of the epithelial cells and in the knob of 
olfactory neurons.  
The finding of these two different patterns in the LBD group is in line with the 
previously reported morphological description of the α-synuclein deposition in the 
CNS neurons and may correspond to former phases of Lewy intracytoplasmic 
inclusions staging in the brain (Gómez-Tortosa, Newell et al. 2000). In particular, 
the previous study found two different patterns of Lewy bodies distribution in 
paralimbic cortices, hence our results may represent a starting point from which to 
trace the differential pathological pathways. 
In the few OM samples of MSA patients, we have seen a remarkable 
intensification of the phosphorylated isoform signal, concomitantly with the 
normal expression of the total α-synuclein. Even in this case, it is possible that the 
lower detection of the total α-synuclein in the cytosolic compartment of ONs is 
correlated with the more-extraneuronal glial implication of the pathology in the 
MSA phenotype (Tu, Galvin et al. 1998). 
In the RBD group, the increase of expression in the total isoform was less marked 
than that in the phosphorylated isoform. A strong increase of the P-Ser 129 with a 
web-shape deposition within the nucleus has been often found.  
Our results support the mechanism of general α-synuclein overexpression just 
reported in genetic forms of PD (Singleton, Farrer et al. 2003).  
The novelty emerging from our study is that, beside a quantitative increase of the 
general protein expression, in the olfactory epithelium, we also observed a 
qualitative alteration in the protein distribution, which was well mirrored in the 
variations of the α-synuclein expression pattern. In particular, each specific form 
96 
 
of synucleinopathy analyzed owned a distinctive pattern of expression for both 
markers, and above all, the phosphorylated isoform showed the major quantitative 
and qualitative variance between groups. 
We think that stochastic events could evoke a transient α-synuclein over-
expression, so that it makes the native protein an available substrate to the 
misfolding mechanisms, which in turn, might trigger the pathology in specific 
districts prone to neurodegeneration. Nevertheless, the α-synuclein expression 
increase could be also, a physiological attempt to preserve the correct synaptic 
function in response to an injury. It seems that the local increase of the synaptic 
protein might serve as a defense reaction against viral infection, especially after 
demonstrating its viral RNA restriction activity in the brain (Beatman, Massey et 
al. 2016). Other quantitative studies on the mRNA and the extent of the related 
protein showed that the levels of soluble α-synuclein found in LBD and PD were 
lower in comparison with the control, although there was no evidence of a 
corresponding decrease in α-synuclein mRNA levels (Quinn, Coulson et al. 2012). 
This discrepancy might reflect an altered protein synthesis or maturation, or the 
removal of the soluble detectable state of the protein, because of the normal 
turnover or the misregulated conversion to an insoluble form. Consequently, the 
protein depletion may decrease the physiologic accomplishment for any cellular 
homeostatic role it may play, contributing to a loss-of-function and neurotoxicity. 
On the basis of these considerations, it is plausible that the α-synuclein increased 
levels we found in the diverse synucleinopathy groups are not the consequence of 
increased gene synthesis, but rather they result from a dysregulation of its 
maturation, or of its turn-over and degradation (Engelender 2008). 
 The aforementioned studies analyzed the α-synuclein levels from different CNS 
areas of patients with severe disease in an advanced stage. Therefore, the results 
might not correspond to the regulation mechanisms of expression in the early 
phases of the disease. For instance, the total α-synuclein rate we found in a long-
term established disease like PD was on average lower compared to the RBD 
group, which is considered a pro-dromal condition of α-synucleinopathy. This 
discrepancy might be due to either a constant protein translocation from the 
olfactory neurons to the olfactory bulb via anterograde transport, or to the 
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continuous misfolding process that renders the normal target protein undetectable 
by the antibodies. Another explanation could be that the levels of the native 
protein expression at the onset of the disease (as RBD condition) increased 
because of the physiological response to restore the cellular homeostasis. 
We hypothesize that protein misfolding events might occur on the ground of the 
continuous injuries that the olfactory neuroepithelium has to face. The ensuing α-
synuclein expression increase becomes considerable at the very early stages of the 
disease. As a result, the dysregulated activation of defense mechanisms 
accelerates the aberrant protein processing leading to aggregation and pathology 
spread within the olfactory bulbs. According to this concept, the variations of the 
α-synuclein patterns we found in each synucleinopathy group, might derive from 
the impairment of distinctive expression pathways and different post-translational 
modifications promoted by the specific defense mechanisms activated. 
Importantly, a larger study must confirm the very promising results obtained so 
far, given their limits because of the small sampling size.  
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5.4 Alpha-synuclein expression patterns in relation to the RT-
QuIC α-synuclein seeding activity in synucleinopathies patients 
 
With regard to the last part of the study, we analyzed the immunocytochemistry 
expression patterns of the α-synuclein in relation to the α-syn RT-QuIC results in 
synucleinopathies' patients. Specifically, we evaluated the variability in the 
expression levels and the distribution patterns of the two α-synuclein markers, 
among RT-QuIC positive and RT-QuIC negative samples. In particular, we 
explored distinctive differences in the expression patterns able to provide insights 
about the seeding activity detected by the α-syn RT-QuIC assay. 
After that, we developed a specific α-synuclein RT-QuIC assay in our laboratories 
that has proven to be specific and sensitive to reveal the aggregation seeding 
activity of α-synuclein (Bongianni, Ladogana et al. 2019).  
Through the immunocytochemistry examination of the α-synuclein expression in 
the same samples tested by α-syn RT-QuIC, we found that the main difference 
between the RT-QuIC positive and RT-QuIC negative specimens lied on the 
distribution of the phosphorylated isoform.  
The P Ser 129 marker owned a nuclear localization in the majority of the cases 
analyzed (23 out 41, 56,11%) mirroring the positivity to the RT-QuIC tests (26 
out 41, 63,4%). In particular, we observed that 88,4% of the RT-QuIC positive 
samples revealed a nuclear detection of the phosphorylated isoform, in a web-
shape or a punctate form.  
The total α-synuclein instead, showed nuclear localization in 30.7% (8 out 26) of 
RT-QuIC positive cases. 75% (6 out 8) of these last positive samples showed 
detection of the total α-synuclein together with P ser 129 in the nucleus. 
On the other hand, we found nuclear positivity of one of the two markers even in 
20% of RT-QuIC negative cases. 
We argue that despite the high sensibility of the nuclear P Ser 129 as a biomarker 
of the α-synuclein seeding activity detected by RT-QuIC, the lower specificity 
might be related to several factors. Firstly, though still controversial, the finding 
of the nuclear localization of α-synuclein and its post-translational isoforms had 
been reported since the original discovery of the protein (Maroteaux, Campanelli 
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et al. 1988) (Wales, Pinho et al. 2013) (Schell, Hasegawa et al. 2009) (Surguchov 
2015). Secondly, the presence of the pre-synaptic protein in the nucleus could be 
also promoted by the physiological DNA damage response pathway (Schaser, 
Osterberg et al. 2019), even in absence of or long before the seeding activity 
induction. The ultimate aspect concerns the issue of the detection of the truncated 
isoforms, which are translocated in the nucleus (Zhou, Xu et al. 2013). Indeed, 
they are largely undetectable by the antibodies, similarly to the misfolded species 
that continuously gobble the proteins and decrease the soluble fractions available 
for the retrieval (Jucker and Walker 2018) (Osterberg, Spinelli et al. 2015). 
However, in rodents, a previous study ascribed the pathological implications of 
the human α-synuclein to their nuclear localization (Wakamatsu, Ishii et al. 2007). 
Moreover, the nuclear localization of α-synuclein has been reported to enhance its 
oligomerization and aggregation capacity (Goers, Manning-Bog et al. 2003) 
(Lázaro, Rodrigues et al. 2014) and its neurotoxicity activity (Kontopoulos, 
Parvin et al. 2006) (Fares, Ait-Bouziad et al. 2014). 
In conclusion, we showed that most of the OM samples positive for the α-syn RT-
QuIC in a cohort of patients suffering from synucleinopathies revealed a nuclear 
localization of the P Ser 129 biomarker, unlike the negative cases, providing a 






For the first time, we provided in this study the phenotypic characterization of the 
human olfactory cells collected by OBg. In particular, we identified the TUJ-1 
neuronal marker for ONs identification. 
We demonstrated that ONs, and in some cases also the neighboring cells, 
constitutively express all the selected NDs-associated proteins under physiological 
conditions, including α-synuclein, APP/β-Amyloid, TDP-43, and tau protein. 
Subsequently, we explored the possibility to distinguish the several 
synucleinopathies based on the α-synuclein expression patterns analysis in the OE 
and we showed a different expression pattern of P-Ser 129 in each distinct 
synucleinopathy. This might be a novel complementary analysis to the existing 
techniques for a more accurate diagnosis of α-synucleinopathy with a clinical 
impact on therapy and prognosis.  
Consequently, we investigated the significance of α-synuclein expression patterns 
variations at the light of RT-QuIC results. Specifically, RT-QuIC positive and 
negative samples revealed distinct qualitative alterations in the distribution 
patterns of P a-syn. In particular, we observed the nuclear deposition of P Ser 129 
in the large majority of the RT-QuIC positive samples. 
The pathological implications of this nuclear localization need to be deeply 
investigated in a larger group of patients. However, the simultaneous analyses of 
immunocytochemistry and RT-QuIC on the same OM sample might be a valuable 
approach to unravel the pathogenetic processing of α-synuclein in its early phase 
of aggregation. 
Of course, these findings, if validated, might be applied in therapeutic trials aimed 
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